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Résumé 
 
 
Objectifs :  Le syndrome métabolique (MetS) est un ensemble de composantes (obésité, 
résistance à l'insuline, intolérance au glucose, dyslipidémie, hypertension) qui sont 
associées à une augmentation du risque de diabète de type 2 et de maladies 
cardiovasculaires.  Aux États-Unis, la fréquence du MetS atteint des proportions 
épidémiques avec une prévalence de 25% de la population.  Les études nutritionnelles 
traditionnelles se sont concentrées sur l’effet d’un nutriment alors que les études plus 
récentes ont déterminé l’effet global de la qualité alimentaire sur les facteurs de risque.  
Cependant, peu d'études ont examiné la relation entre la qualité alimentaire et le MetS.  
 
Objectif: Déterminer l'association entre la qualité alimentaire et le MetS et ses 
composantes.  
 
Méthodes: La présence du MetS a été déterminée chez 88 femmes post-ménopausées en 
surpoids ou obèses, selon la définition du National Cholesterol Education Program Adult 
treatment Panel III alors que la qualité alimentaire a été évaluée selon le Healthy Eating 
Index (HEI).  La sensibilité à l’insuline, la composition corporelle et le métabolisme 
énergétique ont été mesurés. 
 
Résultats: Le HEI corrélait négativement avec la plupart des mesures de masse grasse et 
du poids mais pas avec la sensibilité à l'insuline, l’hypertension et la plupart des marqueurs 
lipidiques.  Cependant, l’HEI corrélait positivement avec LDL-C/ApoB et négativement 
avec le métabolisme énergétique.   
 
Conclusion: Les résultats démontrent que l’HEI est associé avec les mesures de gras 
corporel et la grosseur des LDL.  
 
Mots clés: Obésité, qualité alimentaire, métabolisme lipidique, syndrome métabolique.
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Abstract 
 
 
Background: The metabolic syndrome (MetS) is a constellation of different metabolic 
components including central obesity, insulin resistance, abnormal glucose homeostasis, 
dyslipidemia and high blood pressure which identify individuals at high risk of type 2 
diabetes and cardiovascular events.  In the US, the prevalence of MetS has reached 
epidemic proportion and up to 25% of the population is affected.   
Traditional nutritional studies have focused on a single nutrient.  Recently, measures of 
overall diet quality have been proposed as an alternative to assess diet-related diseases.  
However, few studies have addressed the relationship between diet quality and the MetS.   
 
Objective: To investigate the association of diet quality with the MetS and its components.  
 
Methods:  The presence of the MetS was determined in 88 postmenopausal overweight or 
obese women using the National Cholesterol Education Program Adult treatment Panel III 
definition while diet quality was assessed with the Healthy Eating Index (HEI).  We also 
measured insulin sensitivity, body composition and energy metabolism.  
 
Results: The HEI correlated negatively with most measures of body fat and body weight 
but not with insulin sensitivity, blood pressure and most markers of lipid metabolism.  
However, HEI correlated positively with LDL-C/ApoB and negatively with energy 
metabolism.   
 
Conclusion: Our results demonstrated that HEI is associated with fat distribution and LDL 
size.   
 
Key words: Obesity, diet quality, lipid metabolism, metabolic syndrome. 
v 
 
 
 
 
 
Table of Contents 
 
Résumé ................................................................................................................................. iii 
Table of Contents ................................................................................................................. v 
List of Tables ...................................................................................................................... vii 
List of Figures ...................................................................................................................... ix 
List of Appendices ................................................................................................................ x 
List of Abbreviations .......................................................................................................... xi 
Acknowledgement ............................................................................................................ xvii 
1 Introduction .................................................................................................................. 1 
2 Literature Review of Metabolic Syndrome ............................................................... 3 
2.1 History ..................................................................................................................... 3 
2.2 Current Definitions .................................................................................................. 3 
2.3 Prevalence of the Metabolic Syndrome ................................................................ 10 
2.4 Pathogenesis of the Metabolic Syndrome ............................................................. 13 
2.4.1 Obesity and abnormal body fat distribution ........................................... 14 
2.4.2 Insulin Resistance .................................................................................. 22 
2.4.3 Dyslipidemia .......................................................................................... 29 
2.4.4 Hypertension .......................................................................................... 33 
2.4.5 Other metabolic risk factors ................................................................... 33 
3 Literature Review of Food Quality Indices ............................................................. 37 
3.1 History of food quality indices: ............................................................................. 37 
3.2 General overview on Diet Quality Scores (DQS) ................................................. 38 
3.2.1 Diet quality scores.................................................................................. 39 
vi 
 
 
 
3.3 Different approaches to evaluate diet quality ........................................................ 42 
3.3.1 Approaches Based on Dietary Guidelines ............................................. 45 
3.3.2 Based on Mediterranean diet ................................................................. 56 
3.3.3 Other indices adapted from MDS .......................................................... 57 
4 Rational ....................................................................................................................... 64 
5 Research design and method..................................................................................... 65 
5.1 Subjects ................................................................................................................. 65 
5.2 Study Design ......................................................................................................... 66 
5.3 Methods ................................................................................................................. 67 
5.3.1 Blood samples ........................................................................................ 67 
5.3.2 Insulin sensitivity measurement and estimation .................................... 68 
5.3.3 Blood pressure ....................................................................................... 69 
5.3.4 Body composition .................................................................................. 69 
5.3.5 Energy metabolism ................................................................................ 71 
5.3.6 Quantitative and qualitative food intake assessment ............................. 72 
5.3.7 Cardio-metabolic assessment ................................................................. 73 
5.3.8 Statistical analysis .................................................................................. 74 
6 Results ......................................................................................................................... 75 
7 Discussion.................................................................................................................... 84 
8 Conclusion and Future Work ................................................................................... 87 
REFERENCES ................................................................................................................... 88 
APPENDICES .................................................................................................................... xx 
 
vii 
 
 
 
List of Tables 
 
Table 1. Definitions of the metabolic syndrome based on consensus statement .................. 5 
Table 2. Specific ethnic waist circumference values (adopted from IDF consensus 
worldwide definition of metabolic syndrome) [24] ....................................................... 9 
Table 3. Prevalence of the metabolic syndrome (%) using NCEP ATPIII and WHO criteria 
among non-diabetic adults (30-79 years) in the Framingham Offspring study (1991-
95) and San Antonio Heart studies (1992-96) [31] ...................................................... 13 
Table 4. Health risk as a function of waist circumference and BMI [42] ........................... 15 
Table 5. Values for diagnosis of diabetes and other categories of hyperglycaemia [26] .... 28 
Table 6. Mathematical models for insulin resistance assessment [88] ............................... 29 
Table 7. Additional metabolic measurements ..................................................................... 36 
Table 8. Overview of the attributes included in the existing diet quality scores [7] ........... 43 
Table 9.Overview of existing diet quality scores and studies in which they have been used 
and/ or evaluated [7] .................................................................................................... 44 
Table 10. Components of Healthy Eating Index (HEI-90) [15] .......................................... 46 
Table 11. Recommended numbers of servings per day per energy intake [15] .................. 47 
Table 12.  Criteria used in Canadian adaptation of the Healthy Eating Index (HEI-Ca) [18]
 ...................................................................................................................................... 49 
Table 13.  Recommended daily intakes for the original HEI, a HEI-05, and HEI-2005, 
adapted from [191] ....................................................................................................... 51 
Table 14. Overview of existing diet quality scores, their basis, index components, and 
scoring method [211] ................................................................................................... 59 
Table 15. Overview of the association of dietary indexes and scores with nutrient 
adequacy, biomarkers of health, disease outcome and mortality [7] ........................... 61 
Table 16. Physical characteristics of overweight and obese postmenopausal women (n=88)
 ...................................................................................................................................... 77 
Table 17. Cardio-metabolic characteristics of overweight and obese postmenopausal 
women (n=88) .............................................................................................................. 78 
viii 
 
 
 
Table 18. Healthy Eating Index (HEI) score and sub scores for overweight and obese 
postmenopausal women (n=88) ................................................................................... 79 
Table 19. Number of subjects according to HEI-Ca categories .......................................... 79 
Table 20. Healthy Eating Index (HEI) score according to the number of metabolic 
syndrome components in overweight and obese postmenopausal (n=88) ................... 80 
Table 21. Comparison of the Healthy Eating Index (HEI) between women with and 
without metabolic syndrome ........................................................................................ 81 
Table 22. Bivariate correlations of physical characteristics with Healthy Eating Index 
(HEI) (n=88) ................................................................................................................ 82 
Table 23. Bivariate correlations of cardio metabolic characteristics with Healthy Eating 
Index (HEI) (n=88) ...................................................................................................... 83 
 
Table A-I. Scores of Healthy Eating Index Components (n=7643)* [15] ........................ xxii 
Table A-II. Diet Quality of Montreal-Area Adults Needs Improvement: Estimates from a 
Self-Administered Food Frequency Questionnaire Furnishing a Dietary Indicator 
Score [18] .................................................................................................................. xxiii 
Table A-III. Healthy Eating Index Scores Are Associated With Blood Nutrient 
Concentrations in the Third National Health and Nutrition Examination Survey [209]
 ................................................................................................................................... xxiv 
Table A-IV. Validation of Healthy Eating Index with Use of Plasma biomarkers in a 
clinical sample of women [208] ................................................................................. xxv 
Table A-V. Predictors of Diet Quality among Overweight and Obese postmenopausal 
women [227] ............................................................................................................. xxvi 
Table A-VI. Adherence to the Dietary Guidelines for Americans and risk of major chronic 
disease in women [210] ........................................................................................... xxvii 
 
ix 
 
 
 
 
List of Figures 
 
Figure 1. NHANES III: Prevalence of metabolic syndrome by age [6] ............................. 11 
Figure 2. Prevalence of obesity and diabetes in adults 1991-2001 [38] ............................. 14 
Figure 3. Association of BMI and waist-to-hip ratio with myocardial infarction risk.  
Vertical bars = 95% CIs [61] ....................................................................................... 18 
Figure 4. The role of abdominal obesity in development of MetS and Type 2 diabetes .... 19 
Figure 5. Role of visceral adipocyte in the development of insulin resistance, type 2 
diabetes, and CVD [80] ................................................................................................ 22 
Figure 6. Metabolic Syndrome Components [6] ................................................................. 23 
Figure 7. Atherogenic dyslipidemia .................................................................................... 30 
Figure 8. A simplified model relating insulin resistance to dyslipidemia and cardiovascular 
disease [96] .................................................................................................................. 32 
 
x 
 
 
 
List of Appendices 
 
Appendix 1. Canadian Food Guide, 1997 ........................................................................... xx 
Appendix 2. Tables for mean comparison of HEI ............................................................ xxii 
Appendix 3. Consent form of the Weight-Loss Weight-Regain (WLWR) study .......... xxviii 
 
xi 
 
 
 
 
List of Abbreviations 
 
AHA/ NHLBI American Heart Association/National Heart, Lung, 
and Blood Institute 
AHEI Alternate Healthy Eating Index  
AM Ante meridiem 
BMI Body mass index 
BP Blood Pressure 
CA 
CB1 
Canada 
Cannabinoid receptor type 1 
CE Cholesterylester 
CERFM Faculty of Medicine Ethics Committee 
CETP Cholesterylester transfer protein 
CI Confidential Interval 
Cm Centimetre 
CRP C-reactive protein 
CSFII Continuing Survey of Food Intake by Individuals  
CT  Computed tomography  
CVD Cardiovascular Diseases 
DECODE Diabetes Epidemiology Collaborative Analysis of 
Diagnostic Criteria in Europe 
DGI Dietary Guideline Index 
DLW Doubly labelled water  
xii 
 
 
 
DPP Diabetes Prevention Program  
DQI Diet Quality Index 
DQI-I Diet Quality Index International  
DQI-R Diet Quality Index Revised 
DQS Diet Quality Scores  
DXA Dual Energy x Ray Absorptiometry  
EDTA Ethylene-diamine tetracetic acid  
EGIR European group for Insulin resistance  
EHC Euglycemic-hyperinsulinemic clamp  
FBQI Food Based Quality Index  
FFA Free Fatty Acids 
FFQ Food Frequency Questionnaire 
FPI Food Pyramid Index 
G Gram 
GE General Electric 
GIR  Glucose infusion rate  
h Hour 
HDI Healthy Diet Indicator 
HDL-C High density lipoprotein Cholesterol 
HEI Healthy Eating Index  
HEI-90 Original Healthy Eating Index 
HEI-Ca Canadian HEI 
HFI Healthy Food Index 
xiii 
 
 
 
HMG-CoA 
Reductase 
3-hydroxy-3-methyl-glutaryl-CoA reductase  
HOMA-IR Homeostasis Model Assessment of Insulin 
Resistance 
IDF  International Diabetes Federation 
IDL Intermediate density lipoprotein 
IFG Impaired Fasting Glycaemia  
IGT Impaired Glucose Tolerance  
IL-6 Interleukin 6 
IR Insulin Resistance  
IRAS Insulin Resistance Atherosclerosis Study  
IST Insulin suppression test 
kcal/day  Kilocalorie per day 
kg/m2 Kilogram per square meter 
LDL-C Low density lipoprotein-cholesterol 
LDL-C/ApoB Ratio of low density lipoprotein cholesterol to 
Apolipoprotein B  
MAI Mediterranean Adequacy Index 
MAR Mean adequacy ratio 
MCP1 Monocyte chemotactic protein-1 
MDQI Mediterranean Diet Quality Index 
MDS 
 
Mediterranean Diet Score 
meq/L  Milliequivalent per liter 
xiv 
 
 
 
MetS Metabolic Syndrome 
Mg Milligram  
Mg/dL Milligram per decilitre 
Mg/g Milligram per gram  
min Minute 
MMHG Millimeter mercury column   
mmol/L  Millimole per liter  
MONET Montreal Ottawa New Emerging Team  
MRI Magnetic Resonance Imaging  
NAR The Nutrient Adequacy Ratio  
NCEP ATPIII National Cholesterol Education Program Adult 
treatment Panel III 
NF-B Nuclear Factor Kappa B 
NHANES National Health and Nutrition Examination Survey 
OGTT Oral Glucose Tolerance Test  
OR Odd Ratio 
PAEE Physical Activity Energy Expenditure  
PAI-1 Plaminogen Activator Inhibitor 1 
QUICKI Insulin sensitivity Check Index  
RDA Recommended Dietary Intake 
REE Resting Energy Expenditure  
RISC Relationship between Insulin Sensitivity and 
Cardiovascular disease )  
xv 
 
 
 
ROS  Reactive oxygen species  
SAT Subcutaneous adipose tissue 
SD. Standard Deviation 
SD-LDL Small dense -low density lipoprotein 
SiOGTT, Simple index assessing insulin sensitivity from 
OGTT measurements 
TDZ Thiazolidinediones  
TEE Total energy expenditure 
TG Triglycerides 
TIDE  Thiazolidinedione Intervention With Vitamin D 
Evaluation 
TNF- Tumour necrosis factor alpha 
TSH Thyroid stimulating hormone 
U/L Unit per liter 
UK United Kingdom 
USA United States of America 
VAT Visceral adipose tissue 
VLDL-C  Very low density lipoprotein-cholesterol  
WHO World Health Organization 
WHR Waist to hip ratio 
WI Wisconsin 
ß-cells BETA Cells 
g/ min Micro gram per minute 
xvi 
 
 
 
μg/h Microgram per hour 
μM/ml Micro Mol per milliliter 
μU/m2/min Micro Unit per square meter per minute 
xvii 
 
 
 
Acknowledgement 
 
 
This thesis is a part of Montreal Ottawa New Emerging Team (MONET) Weight 
loss-Weight Regain (WLWR) study which is carried out at the Plateforme de recherche en 
obésité, métabolisme et diabète (PROMD) laboratory at the Institut de Recherches 
cliniques de Montréal (IRCM). It is my pleasure to thank all members of the MONET-
WLWR group who have provided a friendly environment for me. This thesis would have 
not been completed without their cooperation.    
 
First and foremost, I would like to convey my sincere gratitude and deep 
appreciation to my supervisor Dr. Rémi Rabasa-Lhoret and co-supervisor Dr. Lise 
Coderre, who gave me the great opportunity to pursue my Master study in a friendly and 
supportive atmosphere. It has been my greatest honour to be a part of their research group. 
I have been motivated and inspired by their priceless supports and guidance at every step 
of my research. 
 
My special thanks are due to my dear friend and colleague, Marie-Eve Lavoie, 
who has always supported me with her knowledge and experience and inspired me with her 
attitude and character.  
 
My sincere gratitude is extended to Dr. Olivier Receveur, who has made available 
his valuable supports in a number of ways before and after my admission to the Master 
program. I am grateful to Dr. Irene Strychar for her helpful encouragements and advices 
during my Master study. I would like to express my gratitude to Dr. Eugenio Rasio and 
Dr. Olivier Receveur for accepting to be part of the jury. I would like to thank Dr. May 
Faraj for her helpful discussions and recommendations. Moreover, I would like to thank 
Dr. Dominique Garrel for giving me the chance to start my research at the Université de 
Montréal.  
 
xviii 
 
 
 
I warmly thank my friends and officemates, Anne-Sophie Brazeau and Belinda 
Elisha, who have helped me a lot to finish my thesis. 
 
I am deeply indebted to my wonderful parents, Fahimeh and Morteza, who have 
stood by me with their unconditional love and everlasting supports and never let me fall. 
The words cannot express how much I adore them. I will never forget what they have been 
through to let me find my own way. I could have not tolerated these years of living away 
from home without their encouragement and compassion. 
 
At last but definitely not least, I would like to express my wholehearted affections 
and gratitude to the wonderful person who has been supporting me by his utmost 
comprehension throughout my studies. My lovely husband Mohsen, there is no word that 
can say how grateful I am to have you by my side. 
 
 
 
xix 
 
 
 
 
 
To My Dearest in the World 
My MoM and Dad 
Fahimeh &Morteza 
FOR THEIR GREAT HEARTS 
& 
To My Special Friend and Husband 
Mohsen 
FOR ALL HE IS 
 
 
 
1 
 
 
 
1 Introduction 
 
The metabolic syndrome (MetS) is defined as a cluster of different metabolic disorders 
such as obesity, insulin resistance, dyslipidemia, and high blood pressure. The MetS is 
considered as an important risk factor for type 2 diabetes and cardiovascular diseases 
(CVD) [1]. It has been shown that the prevalence of CVD in people with MetS is 50-60% 
higher than those without MetS [2]. In addition, among the subjects without CVD or 
diabetes, those with MetS have greater risks of CVD and type 2 diabetes than those 
without MetS [3]. Furthermore, the San Antonio Heart Study [4] has identified the Mets as 
a predictor of diabetes. According to the Third National Health and Nutrition Examination 
Surveys (1988-1994 and 1999-2002 [5, 6]), the MetS is highly prevalent in the US and is 
an important burden for the US health care sector.  
 
The association of diet with CVD and obesity has been investigated by several 
traditional nutritional epidemiological studies. These studies focused on the effects of 
single nutrients, dietary components, or food on the disease processes [7]. However, these 
studies could not show the overall role of dietary quality or dietary patterns on disease 
protections. Therefore, during the last decade several observational and interventional 
studies have reported that dietary patterns are stronger predictor for all-cause mortality and 
CVD than a single nutrient or food component [8-11]. In 1970, the development and 
improvement of dietary patterns resulted in the emergence of several diet indices that have 
been validated by assessing the correlation of the index scores with health outcomes [7, 12, 
13]. Although the associations of overall dietary quality with all-cause mortality, chronic 
disease risk, and biomarkers of CVD have been discussed in several studies [9-12], only 
few studies have investigated the role of diet in MetS [14]. Among all diet indices, the 
Healthy Eating Index (HEI) has been validated by several studies and has been found to be 
a useful tool for estimating the overall dietary patterns [9, 10, 15]. Moreover, recent studies 
have indicated that HEI correlates with chronic diseases and obesity [16, 17]. Importantly, 
this index has been specifically validated for the Quebec population [18].  
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The aim of our study was to investigate the association of diet quality, which is 
evaluated by the Healthy Eating Index (HEI), with MetS and its components in overweight 
and obese postmenopausal women who participated in the Montreal Ottawa New 
Emerging Team (MONET) Weight-loss Weight Regain (WLWR) study.   
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2 Literature Review of Metabolic Syndrome 
2.1 History 
Currently, there exist multiple definitions for the metabolic syndrome, and these 
definitions have changed considerably over time.  The first description of this syndrome 
was proposed in 1920 when the Swedish physician Kylin described the metabolic 
syndrome (MetS) as a cluster of hypertension, hyperglycaemia, and gout [1, 19].  Two 
decades later, Vague denoted that a particular obesity phenotype, namely upper body 
adiposity (android or men type obesity), was associated with metabolic abnormalities 
including diabetes and cardiovascular disease (CVD) [1, 19].  During the 1988 Banting 
lecture, Reaven used the term “Syndrome X” to define a cluster of abnormalities using 
insulin resistance as the central pathophysiological feature [1, 19] owever, he did not 
include obesity as a component of the syndrome [1, 19].  In 1989, Kaplan renamed it “The 
Deadly Quartet”, which was later substituted by the term “Insulin Resistance Syndrome” 
[1, 19].  Under this definition, the MetS is characterized by abdominal (visceral and 
retroperitoneal) obesity and a cluster of other cardiovascular risk factors including 
impaired glucose tolerance (IGT), increased triglycerides (TG), decreased high density 
lipoprotein cholesterol (HDL-C), elevated blood pressure and hyperinsulinemia with 
underlying insulin resistance [1].  Recently, the scientific community agreed that the term 
“Metabolic Syndrome” was the most useful and widely accepted description of this cluster, 
which is a risk factor for CVD and diabetes (if not already present) [19]. 
2.2 Current Definitions 
The MetS is a cluster of different conditions, and not a single disease with a 
specific cut off point. Therefore, multiple definitions have been developed so far in the 
literature for this syndrome.  Currently, there are six independent definitions of the MetS 
[19], which are presented as follow and will be briefly discussed thereafter. 
• World Health Organization (WHO) [20] 
• The European Group for the study of Insulin Resistance (EGIR) [21] 
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• The National Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATPIII) [22] 
• The American Association of Clinical Endocrinology [1, 23] 
• The International Diabetes Federation (IDF) [24] 
• The American Heart Association/National Heart, Lung and Blood Institute [25] 
The four most currently used definitions are summarized in Table 1. 
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Table 1. Definitions of the metabolic syndrome based on consensus statement 
 
Definition WHO [20, 26]  EGIR [21] NCEP ATPIII [22]  
IDF [24] 
Criteria Insulin resistance + 2 factors below 
Insulin resistance + 
2 factors below 
3 or more factors 
below 
Central obesity + any 
2 factors below 
Insulin 
Resistance 
• Type 2 diabetes or 
• Impaired fasting glucose or 
• Impaired glucose tolerance  
• Evidence of insulin 
resistance 
• Insulin Resistance 
• Fasting 
hyperinsulinemia 
(> 75th percentile) 
  
Plasma 
glucose 
• Type 2 diabetes or 
• Impaired fasting glucose or 
• Impaired glucose 
tolerance  
• Evidence of insulin 
resistance 
• >6.1 mmol/L 
(110 mg/dl) 
but non-diabetic 
•  6.1 mmol/L (110 
mg/dl) 
• FPG  5.6 mmol/L 
(100 mg/dl)  
or 
• Type 2 diabetes 
Obesity 
• BMI > 30 kg/m2 or 
• WHR > 0.9 Men 
• WHR > 0.85 Women 
• Waist 
Circumference 
Men  94 cm  
(37 in) 
Women  80 cm 
(31.5 in) 
• Waist 
Circumference 
Men > 102 cm 
(40 in) 
Women > 88 cm 
(35 in) 
• Central obesity 
• Specific ethnic 
waist circumference 
values 
Dyslipidemia 
• TG  1.7 mmol/l 
 (150 mg/dl) 
• HDL-C  
Men < 0.9 mmol/l 
 (35 mg/dl ) 
 
Women <1.0 mmol/L 
 (39 mg/dl ) 
• TG > 2.0 mmol/l 
(178 mg/dl) or 
treatment 
• HDL-C <1.0 
mmol/l  (39 
mg/dl)  
or 
•  treatment 
• TG  1.7 mmol/L 
(150 mg/dl) 
• HDL-C  
Men <1.03 mmol/l  
(40 mg/dl) 
Women < 1.29 
mmol/l  
(50 mg/dl) 
• TG  1.7 mmol/L 
(150 mg/dl) 
• HDL-C  
Men <1.03 mmol/l(
40 mg/dl) 
Women < 1.29 
mmol/l (50 mg/dl) 
Hypertension 
•   140/90 mmHg or 
• Treatment 
• >140/90 mmHg 
or 
•  Treatment 
• Systolic >130 
mmHg or  
•  Diastolic > 85 
mmHg  
• Systolic >130 
mmHg or 
•  Diastolic > 85 
mmHg  
or  
• Treatment  
Others 
• Urinary albumin excretion 
rate  20 μg/min or  
• Albumin/creatinine ratio  
30mg/g 
   
WHR: Waist to hip ratio 
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The World Health Organization (WHO) Definition 
The WHO was the first to release a definition for the MetS in 1998-1999 [1, 20, 
26]. Under this definition, insulin resistance is a required component for diagnosis.  Insulin 
resistance can be defined as one of the following: (a) type 2 diabetes, (b) impaired fasting 
glucose (IFG), (c) IGT or (d) for those with normal fasting glucose values (< 110 mg/dl), 
glucose uptake below the lowest quartile for background population under 
hyperinsulinemic-euglycemic conditions [27]. The inflammatory or haemostatic variables 
such as hyperuricaemia, coagulation disorders, and plasminogen-activating inhibitor [19] 
are associated with the MetS and highlighted in WHO.  However, these variables are not 
necessary for the recognition of insulin resistance. 
 
There are some limitations for the WHO definition [1, 19], such as the use of the 
euglycemic-hyperinsulinemic clamp to measure insulin sensitivity.  The utilization of this 
technique is virtually impossible in clinical practice or epidemiological studies. Finally, the 
use of waist to hip ratio (WHR) was criticized since for a similar WHR one subject can be 
obese while another is not.  
 
The European Group for the Study of Insulin Resistance (EGIR) Definition  
Following the publication of the WHO definition in 1999, the EGIR group 
proposed a modified version of it to be used only in non-diabetic subjects.  The EGIR 
proposed to measure fasting insulin levels to estimate insulin resistance and IFG as a 
substitute for IGT.  Since this definition does not require the euglycemic-hyperinsulinemic 
clamp, it is considered as a simpler method to use in clinical practices and in 
epidemiological studies [1, 19].  However, significant problems remain about the 
standardization of insulin assay, which considerably limits both application and 
comparison between studies. 
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The National Cholesterol Education Program Adult treatment Panel III (NCEP 
ATPIII) Definition 
In 2001, the NCEP ATPIII definition was presented as a part of educational 
programme for the prevention of coronary heart disease [1].  The goal of this definition 
was to facilitate diagnosis in clinical practice.  The authors hoped that the simple definition 
could lead to an easier identification and thus implementation of preventive measures for 
CVD and type 2 diabetes [19].  This definition has two major differences as compared to 
the others.  First, it does not include insulin resistance as a required component.  Second, it 
is not “glucose centric”.  Thus, all components are treated with equal importance.  It is 
notable that the NCEP ATPIII definition uses waist circumference as a measure of obesity 
(though with higher cut points than the EGIR) [1, 19].  Unlike the WHO, the NCEP ATPIII 
definition does not mention any other factors such as inflammatory and haemostatic 
variables.  This definition has been widely used due to its simplicity since its components 
are easily and routinely measured in most clinical settings.  On the other hand, some 
studies have shown that NCEP ATPIII fails to identify some patients with insulin 
resistance [22]. 
 
The International Diabetes Federation (IDF) Definition 
In May 2004, the IDF released its statement on the MetS.  The main goals were to 
examine how the current definitions of the MetS could be improved and to reach a 
consensus statement for a new, unifying and worldwide working definition.  They also 
wanted to discuss the treatment of subjects with MetS and the prevention of diabetes and 
CVD [1, 19, 25].  The IDF wanted to provide a definition that  
a. was easy to use in clinical practice, while avoiding the need of measurements 
available in research settings,   
b. facilitated the comparisons across countries and populations, and 
c. highlighted areas where more research was needed. 
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Furthermore, the IDF decided that the definition should have been less “glucose 
centric”.  Moreover, since abdominal obesity was highly correlated with insulin resistance, 
its presence became a necessary diagnosis requirement [25].  The definition of abdominal 
obesity is based on waist circumference with specific ethnic cut off points.  In South 
Asians, Chinese and Japanese, the cut off values for men and women are  90 and 80 cm, 
respectively, while they are  94 and 80 cm for Europeans men and women, respectively.  
Thus, for Caucasians these cut-off points are lower than the ones proposed by the NCEP 
ATPIII ( 102 cm for men and  88 cm for women).  The European cut off points are also 
used for Sub-Saharan Africans, Eastern Mediterranean and Middle East populations, while 
for South and Central Americans the Asian recommendation is used (see Table 2). 
 
 The IDF is the only definition that provides ethnic specific cut off values for waist 
circumferences.  These have been developed based on expert consensus rather than strong 
scientific evidences, which explain the various cut-off points proposed by each 
organisation. 
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Table 2. Specific ethnic waist circumference values (adopted from IDF consensus 
worldwide definition of metabolic syndrome) [24] 
Country/Ethnic group Waist Circumference 
Europids 
Except for the USA, the ATPIII values (102 cm 
men, 88 cm women) are likely to be used  
Men  94cm 
Women  80cm 
South Asians: based on a Chinese, Malay and 
Asian-Indian population 
Men  90cm 
Women  80cm 
Chinese 
Men  90cm 
Women  80cm 
Japanese 
Men  85cm 
Women  90cm 
Ethnic South and Central Americans 
South Asian recommendations 
until more specific data are 
available 
Sub-Saharan Africans 
European recommendations until 
more specific data are available 
Eastern Mediterranean and Middle East (Arab) 
populations 
European recommendations until 
more specific data are available 
These cut off points have been modified in the Canadian Guidelines [28] 
 
The American Association of Clinical Endocrinology (AACE) Definition  
More recently, the AACE released a modification of the NCEP ATPIII definition as 
a position statement on the “insulin resistance syndrome” [23]. The AACE definition 
considered insulin resistance as a core feature and its goal was to identify individuals with 
10 
 
 
 
insulin resistance.  In diabetic subjects, glucose rises while insulin concentrations decline.  
This can lead to a false estimation of insulin sensitivity when surrogate indices are used.  
Since the goal is to measure insulin resistance easily and reliably, diabetic subjects are 
excluded.  The AACE statement does not provide a specific definition for the MetS, and 
allows diagnosis to rely on clinical judgments [1, 19]. 
 
The American Heart Association/National Heart, Lung, and Blood Institute 
(AHA/NHLBI) Definition 
In contrast to the IDF, the AHA/NHLB decided to keep the NCEP ATPIII criteria 
with some minor modifications.  The only difference between the AHA/NHLB and the 
NCEP ATPIII is the reduction of the threshold for impaired fasting glucose from 110 to 
100 mg/dl, which corresponds to the American Diabetes Association criteria for this 
parameter [25]. 
 
2.3 Prevalence of the Metabolic Syndrome 
The prevalence of the MetS will clearly vary depending on the definition applied, 
the ethnicity, and the age of the study population.  The 1988-1994 cross-sectional National 
Health and Nutrition Examination Survey (NHANES) was done on 8814 men and women 
aged 20 years or older [6].  The objective of this study was to estimate the prevalence of 
the MetS in USA as defined by the NCEP ATPIII report.  In this study, the unadjusted and 
age-adjusted prevalence of the MetS were 21.8% and 23.7%, respectively.  The prevalence 
among participants aged 20-29 years was 6.7% while this number increased to 43.5% and 
42% for those aged 60-69 and 70 years or older, respectively.  
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Figure 1. NHANES III: Prevalence of metabolic syndrome by age [6] 
 
The highest age-adjusted prevalence was observed in Mexican-Americans (31.9%) 
while African-American and Mexican-American women had 57% and 26% higher 
prevalence than men, respectively. 
 
Based on the 2000 census data, about 47 million of the US residents or 22% (24% 
after adjustment) have the MetS and approximately 73.9% of them are overweight or 
obese.  There are some differences between previous estimations of the MetS prevalence in 
the US and Europe, in part because of the definitions used and the populations studied [6].  
It has been suggested that the prevalence of the MetS tends to be higher than what 
estimated from 1988-1994 NHANES data due to the increase in the prevalence of obesity 
in the US [6]. 
 
A study by Earl Ford on 3601 American adults aged  20 years from the 1999-2002 
NHANES [6] (Figure 1) showed that the unadjusted prevalence of the MetS was 39% and 
35% according to IDF and NCEP ATPIII definitions, respectively [5].  Based on the IDF 
definition, the unadjusted prevalence of the MetS was 39.9% and 38.1% among men and 
women, respectively, while it was 33.7% and 35.4% among men and women according to 
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NCEP ATPIII [21]. This study, as well as another one from Greece [29], showed that the 
IDF definition led to a higher prevalence of the MetS than the NCEP ATPIII definition.  
However, compared to the study from Greece, the IDF definition seems to better predict 
CVD in middle-aged subjects [30].  Importantly, comparison between the two surveys 
(1988-1994 NHANES and 1999-2002 NHANES) highlights the significant increase in the 
prevalence of MetS over these periods [21].  
 
As shown in Table 3, there are also some differences between the prevalence of MetS 
using NCEP ATPIII and WHO criteria among non-diabetic adults [31].  Furthermore, the 
Diabetes Epidemiology Collaborative Analysis of Diagnostic Criteria in Europe 
(DECODE), in which 10269 subjects were enrolled, suggests that the WHO definition has 
higher hazard ratios for CVD mortality in men than other definitions [32].  Therefore, it is 
still unclear which definition is the most appropriate one. 
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Table 3. Prevalence of the metabolic syndrome (%) using NCEP ATPIII and WHO criteria 
among non-diabetic adults (30-79 years) in the Framingham Offspring study (1991-95) and 
San Antonio Heart studies (1992-96) [31] 
NCEP: National Cholesterol Education Program; WHO: World Health Organization; BMI: body 
mass index 
 
2.4 Pathogenesis of the Metabolic Syndrome 
The pathogenesis of MetS is poorly understood and is likely to be complex and 
multifactorial [19]. Three potential etiological categories of factors have been identified: 
(a) obesity and disorder of adipose tissue, (b) insulin resistance, and (c) a cluster of 
independent factors e.g., hypertension, molecules of hepatic, vascular, and immunological 
origins.  In addition, other factors such as aging, proinflammatory state, hormonal changes, 
genetic profile, physical inactivity, and atherogenic diet (e.g. a diet rich in saturated fat and 
cholesterol) have been implicated in the development of the MetS.  The role of these causal 
factors varies depending on the ethnic group [1] . 
 
 
 
 
White 
N=3224 
Non-Hispanic white 
N=1081 
Mexican-American 
N=1656 
 Men Women Men Women Men Women 
NCEP ATPIII 
Waist circumference (cm) 
 men      102   
 women   88  
26.9 21.4 24.7 21.3 29 32.8 
NCEP ATPIII  
BMI  30 kg/m2 
25.2 17.8 22.1 15 28.4 26.8 
WHO  
BMI  30 kg/m2 
30.3 18.1 24.7 17.2 32 28.3 
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2.4.1 Obesity and abnormal body fat distribution 
As shown in Figure 2, the prevalence of obesity is rising rapidly in USA [33-35].  
According to the WHO [36], at least 1.1 billion adults are overweight among which 312 
millions are morbidly obese. In the last decade, the obesity prevalence has shown a 
dramatic increase of 10-40% in European countries while 50% of adults in Western Europe 
are overweight or obese. Furthermore, in the US 65% of adults are overweight or obese 
that indicates a 40% rise in the prevalence of overweight and 110% increase in the 
prevalence of obesity compared to the last decade [37]. 
 
 
 
Figure 2. Prevalence of obesity and diabetes in adults 1991-2001 [38] 
 
Obesity is most often defined based on body mass index (BMI) by using the 
following formula: weight (kg) divided by height squared (meter).  As shown in Table 4, 
BMI is categorized into normal (20-25), overweight (25-30) and obese ( 30) [39].  
Obesity can also be defined according to the percentage of total body fat, which is defined 
as  25% and  35% in men and women, respectively, or by waist circumference.  Several 
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methods can be used to evaluate the percentage of total body fat, such as skin-fold 
thickness, bioelectrical impedance, Magnetic Resonance Imaging (MRI), Dual Energy X 
Ray Absorptiometry (DXA), underwater weighing (which used water displacement), and 
the BOD POD Gold Standard Body Composition Tracking System (which used air 
displacement). Some techniques also assess fat repartition including DXA, computed 
tomography (CT scan), MRI and waist circumference.  Except for waist circumference, 
most of these techniques are rarely used in clinical practice because of inconveniences (as 
in radiation) and costs [40]. The recommendation for weight management can be made 
based on standardized BMI and waist circumference cut off points.  The US National 
Institute of Health [40] and Scottish Intercollegiate Guidelines Network [41] have defined 
different waist circumference cut off points based on the severity of obesity.  Thus, the cut 
off values of 94 cm in men and 80 cm in women represent moderate obesity, while severe 
obesity is defined as 102 cm in men and 88 cm in women.  However, according to NCEP 
ATPIII, in the US abdominal obesity is defined as a waist circumference of  102 and  88 
in men and women, respectively [40]. The Canadian clinical practice guidelines emphasize 
that for a given BMI, any waist increment increases the health risk associated with obesity 
(Table 4) [42]. 
 
Table 4. Health risk as a function of waist circumference and BMI [42]  
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Ferranini et al. [43]  showed that 35% of individuals with BMIs of 30-35 kg/m2 and 
65% of those over 35 kg/m2 are insulin resistant.  The San Antonio Heart study [44]  
showed that WHR and fasting insulin levels were significant predictors of the MetS. 32% 
of individuals presenting high BMI ( 30 kg/m2) and high waist circumference (102 cm in 
men and 88 cm in women) had developed the MetS as compared to 10% of subjects with 
low BMI and low waist circumference [42].  Furthermore, anthropometric indices remain 
significant predictors of the MetS after adjustment for fasting insulin, a surrogate measure 
of insulin resistance.  The increased prevalence of the MetS, type 2 diabetes, and insulin 
resistance have been paralleled with the increase of obesity prevalence that suggests a role 
for obesity in promoting these diseases.  According to NHANES, the prevalence of the 
MetS rises with increasing BMI [45].  Furthermore, the IDF [1] and the NCEP ATPIII [46]  
consider that the “obesity epidemic” is one of the main reasons for the rise in the 
prevalence of the MetS.   
 
Obesity is also associated with multiple risk factors, which can alone or together 
favour the development of CVD.  These factors include (a) atherogenic dyslipidemia 
(elevated levels of TG, very low density lipoprotein-cholesterol (VLDL-C), low density 
lipoprotein-cholesterol (LDL-C), apolipoprotein B-100 (ApoB) and low levels of high 
density lipoprotein cholesterol (HDL-C) [47]), (b) high blood pressure [48], (c) 
inflammation, and (d) coagulation and fibrinolytic abnormalities which can induce a 
prothrombic state [49-51]. 
 
Body fat distribution 
Obesity can be due to increased adipocyte size (hypertrophy) or adipocyte numbers 
(hyperplasia) [52]. It is believed that bigger adipocytes are more insulin resistant and 
produce more deleterious molecules (such as TNF-α) than smaller adipocytes [52].  A 
large number of cross-sectional and prospective studies have confirmed the proposal of 
Jean Vague [53, 54], which suggested that excessive fat stored in trunk (or abdominal 
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obesity) could be metabolically more damaging than gynoid (also called lower-body, 
peripheral fat, and gluteofemoral fat) obesity.  In fact, abdominal fat correlates better with 
insulin resistance and MetS than lower body obesity [55].  Therefore, in 1983 abdominal 
obesity was  found as a key factor in promoting MetS [56]. 
 
An accumulation of abdominal body fat can occur intraperitonally (visceral fat) or 
subcutaneously.  Excessive visceral fat (VAT) correlated more strongly with insulin 
resistance than other adipose tissue compartments [25, 57].  In addition, a recent study has 
found a strong and independent relationship between intra-abdominal fat (VAT) area and 
the MetS [58].  On the other hand, some studies [59, 60] have observed a significant 
association between excessive subcutaneous abdominal fat and insulin resistance.  In 
addition, this adipose tissue depot has been found to predict the features of MetS [58].  
Several studies have demonstrated that even after correcting for BMI, waist circumference 
is still significantly associated with cardiovascular and all-cause mortality [61] (see Figure 
3). This indicates the important role of abdominal adipose tissue compared to peripheral 
adipose tissue [21, 26, 62].  Importantly, even individuals with a normal BMI can have 
excessive VAT and show the feature of MetS.  In addition, Figure 4 summarizes the role of 
abdominal obesity in development of MetS and Type 2 diabetes. 
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Figure 3. Association of BMI and waist-to-hip ratio with myocardial infarction risk.  
Vertical bars = 95% CIs [61] 
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Figure 4. The role of abdominal obesity in development of MetS and Type 2 diabetes 
 
Role of adipose tissue 
In addition to the role of adipose tissue in heat insulation, mechanical cushioning, 
and TG storage [63], adipose tissue is a key endocrine organ that secretes active endocrine, 
paracrine and autocrine substances in response to different stimulus [64]. Thus, the 
association of obesity (particularly VAT) with metabolic risk factors could be explained 
through the following factors: (a) increased free fatty acids (FFA), (b) ectopic fat 
deposition, (c) altered postprandial lipid buffering, and (d) altered adipocytokine 
production. 
 
Role of Free Fat Acids (FFAs) and ectopic fat deposition 
FFAs are the primary energy source in the fasting state.  They are derived from the 
biolysis of adipose tissue’s triglycerides. This results in an increased FFA which is released 
by adipose tissue and leads to elevated circulating FFA levels. Since FFA uptake in 
different tissues is proportional to their concentrations, increased FFA levels lead to higher 
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tissue uptake of FFA [63]. This increased FFA influx enhances reactive oxygen species 
(ROS) production leading to oxidative stress.  Elevated circulating FFA levels also 
promote fat accumulation in non-adipose tissues that is also called ectopic fat deposition.  
This can occur in muscle, pancreas, kidney, heart, and liver [39]. Ectopic fat deposition is 
toxic for most cells (lipotoxicity) including those from the heart and the pancreas, and can 
lead to lipoapoptosis or lipid-induced programmed cell death.  Lipotoxicity can also cause 
insulin resistance, impaired insulin secretion, and type 2 diabetes [65, 66]. 
 
In the liver, increased fat deposition causes fatty liver, atherogenic dyslipidemia, 
and insulin resistance.  Reduction of insulin action in the liver enhances glycogenolysis and 
increases hepatic glucose output, which accentuates hyperglycaemia in those patients.  
Liver fat accumulation is also associated with increased hepatic synthesis of plasminogen 
activator inhibitor-1 (PAI-1), fibrinogen, and inflammatory cytokines [67]. 
 
In pancreatic β-cells, the combination of excessive lipids (lipotoxicity) and 
hyperglycaemia (glucotoxicity) (that is called gluco-lipotoxicity) appears to be a 
deleterious combination favouring the progression to overt diabetes [68]. 
 
Role of postprandial lipid buffering 
Abnormalities described in the previous section are exacerbated in the postprandial 
state due to lipid intake [69].  During this period, adipose tissue switches from a lipolytic to 
a lipogenic state.  FFA derived from triglyceride rich lipoproteins are drained from the 
plasma wildly by adipose tissue during the postprandial period, while they are released 
softly during fasting period.  The switch between the two states depends not only on the 
adipose tissue functional state but also on the environmental milieu (substrates and 
hormones).  Because insulin plays a major role in lipid synthesis and degradation, insulin 
resistance in obese subjects leads to failure of the buffering function of adipose tissue [70], 
that results in higher plasma postprandial lipids levels. Postprandial lipidemia initiates 
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various processes leading to metabolic abnormalities such as high triglycerides, low HDL-
C, liver abnormalities, inflammation, β-cell dysfunction and apoptosis [71]. 
 
Role of adipocytokines 
Adipose tissue is an endocrine organ that secretes a large number of biologically 
important substances named adipocytokines.  Adiponectin and leptin are anti-inflammatory 
while tumour necrosis factor alpha (TNF-), interleukin (IL)-6, PAI-1, angiotensinogen, 
and resistin have proinflammatory characteristics. As shown in Figure 5, obese individuals 
present elevated amounts of IL-6 and TNF- [72, 73].  Studies have shown that TNF- can 
impair insulin action and inhibit endothelial vasodilatation [72, 74], while resistin is 
associated with obesity and type 2 diabetes [75].  In addition, in people with abdominal 
obesity and high plasma fibrinogen it has been found that high level of PAI-1 leads to 
prothrombic state [76]. 
 
Adiponectin is an antiatherogenic adipocytokine that modulates glucose and fatty 
acid metabolisms.  In obese subjects, excessive adipose tissue is associated with decreased 
adiponectin production, which may alter insulin sensitivity [77-81]. This hormone also 
inhibits TNF- and its downstream regulator, NF-B, and thus may reduce the 
proinflammatory profile.  Hypoadiponectinaemia is associated with high BMI, insulin 
resistance, dyslipidemia, endothelial dysfunction, and increased risk of CVD and type 2 
diabetes [78, 79, 82]. 
 
Another anti-inflammatory adipocytokine is leptin, which controls energy 
homeostasis and is an appetite suppressant.  Leptin enhances fatty acid oxidation and 
protects against fatty liver.  However, most obese subjects show leptin resistance as 
reflected by the high plasma leptin levels. 
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Figure 5. Role of visceral adipocyte in the development of insulin resistance, type 2 
diabetes, and CVD [80] 
 
2.4.2 Insulin Resistance 
Insulin is a major anabolic hormone secreted by the pancreatic β-cells, which is 
essential for appropriate tissue development, growth, and maintenance of glucose 
homeostasis.  Insulin has several roles in the body, such as decreasing postprandial glucose 
level due to increased glucose uptake into skeletal muscle and adipose tissue, and 
decreasing hepatic glucose production via inhibition of gluconeogenesis and 
glycogenolysis.  Insulin also increases lipid synthesis in liver and fat cells and decreases 
fatty acid release from adipose tissue.  Insulin regulates over 700 genes involved in 
metabolic and cellular functions [81].  Thus, altered insulin action may lead to elevated 
circulating glucose and FFA levels. Hyperglycaemia may promote cell damage 
(glucotoxicity) through multiple mechanisms including (a) increased production of ROS 
leading to oxidative stress, (b) increased formation of glycation end products [82], (c) 
increased hexosamine pathway, and (d) accumulation of intracellular diacylglycerol 
leading to the activation of protein kinase C, with diverse intra and extra cellular 
consequences [83].  Moreover, studies have shown that glucotoxicity may exacerbate 
insulin resistance and thus it may induce a vicious circle. 
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Several factors can contribute to the development of insulin resistance, such as 
genetic predisposition, ageing, sedentary life style, nutritional factors, obesity, 
hypertension and inflammation. Insulin resistance can trigger other components of the 
MetS such as obesity, type 2 diabetes, atherogenic dyslipidemia, hypertension, 
prothrombic and inflammatory state (Figure 6).  Insulin resistance exists at any given level 
of body fat, and variation in insulin resistance may vary more than 10-fold even in 
apparently healthy normal weight subjects [84].  Interestingly, insulin resistance in normal 
weight subjects displays metabolic abnormality reminiscent of the MetS [85].  They have 
been identified as Metabolically Obese Normal Weight (MONW), an early phase of the 
MetS [86].  However, studies have shown that insulin resistance usually rises with the 
increase in body fat content [87].  It has been shown that basal and total 24-h rates of 
insulin secretion are 3-4 times higher in obese subjects compared to their lean counterparts 
[88].  On the other hand, variation of insulin sensitivity exists even within the obese 
population. A subset of obese individuals, who remain insulin sensitive, has been identified 
[88].  
 
 
 
Figure 6. Metabolic Syndrome Components [6] 
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Insulin resistance is more common in some populations (e.g. South Asians) even 
with BMI < 25 kg/m2, and it contributes to the high prevalence of type 2 diabetes and 
premature CVD.  Insulin resistance is present in the majority of people with MetS and it is 
one of the components of the MetS definitions in the WHO and EGIR as discussed 
previously. The association of insulin resistance or hyperinsulinemia with MetS 
components has been shown in a large number of studies.  It is widely believed that insulin 
resistance is a central feature of the MetS and could be even more important than obesity 
[89, 90].  Bruneck et al. [91] have demonstrated that in subjects aged 40-79 years, the 
degree of insulin resistance assessed with the homeostasis model assessment (HOMA), 
which is a widely used fasting surrogate measure of insulin resistance, was correlated with 
the number of metabolic abnormalities.  Karelis et al. have confirmed this association using 
the euglycemic-hyperinsulinemic clamp [92].  Several studies have shown that insulin 
resistance is strongly associated with most components of MetS, including atherogenic 
dyslipidemia and a proinflammatory state, while a weak association with hypertension and 
the prothrombic state has been reported [93-95].  The complexity of these links resulted 
from  multiple causes that included (a) interaction of genes predisposing to insulin 
resistance with those modulating lipid metabolism, and (b) blood pressure and artery wall 
biology [96].   
 
Reaven and Farquhar [97] began to define the insulin resistance syndrome and its 
links to both hypertriglyceridemia and CVD.  In the following decades, several prospective 
cohort studies have shown the association between hyperinsulinemia or surrogate measures 
of insulin resistance, and risk of atherosclerosis even in non-diabetic subjects [88, 96].  For 
example, the San Antonio Heart Study reported that higher insulin levels were associated 
with a 2.5 fold increased risk of CVD even after controlling for blood pressure, medication, 
family history, age, BMI, plasma lipid levels, and tobacco and alcohol use [98].  The 
Helsinki Policemen Study, which included 1000 men followed up for a period of 9.5 years, 
has shown that plasma insulin levels were associated with coronary heart disease [99].  
25 
 
 
 
Similar results were obtained by Ducimetier et al. in 7000 non-diabetic middle-aged men 
[100]. Although some data suggest that insulin resistance and hyperinsulinemia are two 
independent risk factors for CVD, their associations have not been confirmed yet in large-
scale clinical trials [101].  The need for prospective evaluation of insulin resistance as an 
independent CVD risk factor led the EGIR to design the Relationship between Insulin 
Sensitivity and Cardiovascular disease (RISC) study.  Thus, 1500 healthy individuals in 13 
countries were examined for insulin resistance and CVD risk, prospectively after 3 and 10 
years.  The study has shown that insulin resistance precedes the development of 
intermediate phenotypes (obesity, dyslipidemia, hypertension) while the association with 
atherosclerosis is still being evaluated [102]. However, there are increasing evidences that 
insulin resistance may be directly atherogenic.  The Insulin Resistance Atherosclerosis 
Study (IRAS) showed a direct relationship between insulin resistance and the carotid artery 
intima thickness even after adjusting for several associated risk factors [103]. 
Hyperinsulinemia could be atherogenic by stimulating the division and migration of 
vascular smooth muscle cells of the vessel wall, and by promoting endothelial dysfunction.  
Supporting a role for insulin in this process, thiazolidinediones (TDZ) and other 
peroxisome proliferator-activated receptor (PPAR)-γ ligands, which increase insulin 
sensitivity, inhibit smooth muscle cell proliferation and migration [104, 105].  However, 
the effect of TDZ administration on CVD risk is still controversial.  Thus, randomised 
controlled trials with type 2 diabetic patients receiving TDZ have demonstrated no 
reduction in CVD risk [106]  or equivocal results [107], while meta analyses have 
suggested increased CVD risk [108-111].  Targeting insulin resistance to reduce CVD risk 
is currently tested in a huge randomized trial, namely the Thiazolidinedione Intervention 
with Vitamin D Evaluation (TIDE) study. 
 
Methods to assess insulin sensitivity/resistance  
There is no accepted cut off value that defines insulin resistance.  As discussed 
previously, the absence of a standardized insulin assay is a major limitation.  Insulin 
resistance affects various tissues at different levels.  Thus, various methods and parameters 
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capturing different aspects of insulin resistance have been developed (including those 
specified below).  One drawback is that since different methods are used to assess insulin 
resistance, the results obtained are not always comparable [112]. 
 
Hyperinsulinemic euglycemic clamp: This method is currently the accepted gold standard 
for investigating and quantifying insulin resistance [113].  The response of an individual to 
insulin is measured through infusion of a fixed dose of insulin to reach a hyperinsulinemic 
plateau, and through a variable glucose infusion aimed to maintain a constant serum 
glucose level (5.0-5.6 mmol/L or 89-90 mg/dL).  To assess liver insulin resistance, low 
doses of insulin are more useful whereas high doses of insulin are better for assessing 
peripheral (muscle and fat) insulin resistance.  Insulin resistance is calculated according to 
the rate of glucose infusion during the last 30 min of the test, which usually lasts for 2 to 3 
hours.  Stable isotopes can be used to measure more precisely the hepatic glucose 
production and the tissue utilisation.  This test is done more in research than in clinical 
setting, because it is costly and rather complex to perform [76].  Despite the fact that it is 
considered as the gold standard, numerous technical variations exist such as the amount of 
insulin used, the length of the test, etc. [114]. 
 
Insulin Suppression Test (IST): After an overnight fast, somatostatin (250 μg/h) is infused 
intravenously to suppress endogenous insulin production.  Simultaneously, glucose and 
insulin are infused over 150 min at constant rate.  The resultant steady state plasma glucose 
concentration obtained during the last 30 min of the test represents an estimation of insulin 
sensitivity. The higher the glucose concentration goes, the more the individual is insulin 
resistant.  The IST was the first test that utilized steady state plasma insulin levels to 
promote disposal of a glucose load.  However, and similar to the clamp, the IST is 
impractical in large epidemiological studies.  Moreover, there is a risk of hypoglycaemia in 
insulin-sensitive subjects.  Finally, the IST can provoke glycosuria in type 2 diabetes 
subjects leading to an underestimation of insulin resistance.  Since the clamp and the IST 
are expensive, complex to perform, and not applicable for routine clinical practice, 
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mathematical models have been developed to estimate insulin resistance using insulin and 
glucose levels either in the fasting state or during the OGTT. 
 
Oral glucose tolerance test (OGTT): In the absence of fasting hyperglycaemia, OGTT is 
the recommended test for the diagnosis of diabetes.  Glucose and insulin values collected 
during the OGTT are used to calculate various indices to estimate insulin sensitivity.  For 
examples, Bastard et al. have proposed the simple oral glucose tolerance test (SiOGTT), 
which has been validated in various clinical situations [115]. Usually, OGTT-derived 
indices correlate better with the euglycemic hyperinsulinemic clamp than fasting based 
indices.  Thus, the OGTT offers the ability to derive physiological information from a 
clinical test.  However, the length (2-h) as well as the need for repeated blood sampling is a 
limitation. 
 
Usually the OGTT is performed in the morning (7-8 am) as glucose tolerance 
shows a diurnal rhythm with a significant decrease in the afternoon.  The patient should be 
fasting for the previous 8-14 h but water is allowed.  Table 5 shows the criteria for the 
diagnosis of IFG, IGT and diabetes using this test.  Ideally, diet and exercise should be 
standardized during the previous day (sufficient carbohydrate intake and no unusual 
exercise) to ensure adequate glycogen store.  During an illness, the test should not be 
performed because the results may not reflect the patient’s glucose metabolism in a healthy 
state.  In addition, it is important to adjust the glucose load to the weight in a person with 
body weight less than 43 kg. 
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Table 5. Values for diagnosis of diabetes and other categories of hyperglycaemia [26] 
 Serum glucose concentration mmol/L (mg/dL) 
 Venous Capillary Plasma Venous 
Normal  
Fasting 
2-h post glucose load 
  
 
<6.1 (< 110) 
<11.1(< 200) 
Impaired Fasting Glycemia (IFG) 
Fasting and 
 
2-h post glucose load (if measured) 
 
 5.6 ( 100) and 
<6.1 (110) 
<6.7 (<120) 
 
 5.6 ( 100) and 
<6.1 (<110) 
<7.8 (<140) 
 
 6.1 ( 110) and 
 < 7.0 (< 126) 
<7.8 (< 140) 
Impaired Glucose Tolerance (IGT)
Fasting (if measured) and 
2-h post glucose load 
 
<6.1(<110) and 
 6.7 ( 120) 
 
<6.1 (<110) and 
 7.8 ( 140) 
 
<7.0 (< 126) and 
 7.8 ( 140) 
Diabetes  
Fasting or 
2-h post glucose load 
 
 6.1 ( 110) 
 10.0 ( 180) 
 
 6.1 ( 110) 
 11.1 ( 200) 
 
 7.0 ( 126) 
 11.1 ( 200) 
 
Fasting based indices 
The first and the most well accepted model, which was proposed by Matthews et al. 
[116], is the HOMA.  It is a mathematical model for estimating insulin resistance from 
plasma glucose and insulin values.  Also a close alternative, namely the quantitative insulin 
sensitivity check index (QUICKI), has been proposed by using log transformed glucose 
and insulin values [117].  Both of these models correlate well with in vivo measures of 
insulin sensitivity.  Although these two methods are widely available and have a predictive 
value in the development of type 2 diabetes, they have not been routinely used in clinical 
practices due to lack of evidence-based data that can guide the clinician to make decisions 
[76].  Table 6 shows the formula of these two mathematical models for insulin resistance 
assessment. 
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Fasting serum insulin level can also be used as a marker of insulin resistance since 
studies have shown that the two rise in parallel [118].  It has been found that fasting insulin 
level is a good surrogate in non-diabetic obese postmenopausal women [112].  Insulin 
cannot be used in diabetic patients because at some point plasma insulin falls and does not 
reflect insulin resistance any more.  Furthermore, pharmacological treatments can bias 
plasma insulin values (e.g. insulin and sulfonylurea). 
 
Table 6. Mathematical models for insulin resistance assessment [88] 
HOMA-IR 
Homeostasis Model Assessment of 
Insulin Resistance 
Fasting insulin (μM/ml) X fasting glucose 
(mmol/l)/22.5 
QUICKI  
Quantitative Insulin-Sensitivity Check 
Index 
1/[log fasting insulin + log fasting glucose (mg/dl)] 
 
2.4.3 Dyslipidemia 
Another component of the MetS is atherogenic dyslipidemia.  As shown in Figure 
7, this condition is defined as an aggregation of lipoprotein abnormalities including 
increased levels of serum TG, ApoB, and small LDL-C, as well as reduced level of HDL-
C.  All of these abnormalities are independently atherogenic.  Dyslipidemia is strongly 
regulated by genetic variation, diet, alcohol intake and physical activity.  Therefore, there 
is a considerable variation in the dyslipidemia phenotype in response to obesity and/or 
insulin resistance [46]. 
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Figure 7. Atherogenic dyslipidemia 
 
As shown in Figure 8, cholesterol metabolism is regulated mainly by five 
lipoprotein groups: (a) chylomicrons, (b) VLDL, (c) intermediate density lipoprotein, (d) 
LDL, and (e) HDL.  VLDL is assembled in the liver from cholesterol and apolipoproteins.  
It transports cholesterol and triglycerides within the body.  Two forms of VLDL exist, 
namely VLDL1 and VLDL2, which are assembled and secreted from the liver.  VLDL1 is 
larger and contains more TG compared to VLDL2.  VLDL 1 is pro-atherogenic through 
two main effects: 1) it is converted to LDL in plasma and 2) it decreases HDL level.  Over-
secretion of VLDL 1 has been associated with insulin resistance and type 2 diabetes [119]. 
 
LDL transports cholesterol and triglycerides from the liver to peripheral tissues 
while HDL transports cholesterol mostly to the liver.  The cholesterol delivered to the liver 
is either recycled into new lipoproteins or excreted into the bile and the intestine.  ApoB is 
the primary component of LDL and is absolutely required for its formation.  ApoB is also 
found in VLDL.  Importantly, there is one ApoB molecule per LDL and VLDL.  Usually, 
more than 90% of ApoB is bound to LDL-C.  It is believed that ApoB can act as a ligand 
for LDL receptors, thereby allowing cholesterol to transport into the cell.  Since there is 
only one ApoB per LDL particle, and since in healthy subjects more than 90% of ApoB is 
found in LDL particles, determination of whole plasma ApoB can be considered as a 
reasonable approximation of LDL-Number. 
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It is well known that high LDL-C levels are predictors of CVD [100, 120, 121]. 
There are extensive evidences for the observation that reducing LDL-C through inhibition 
of a key enzyme for cholesterol formation (HMG co-A reductase) reduces CVD risk [122].  
Studies have identified seven distinct LDL subclasses based on their diameters [123, 124]. 
The LDL size is primarily inherited.  Several case control and prospective studies have 
shown that smaller LDL particles are better predictors of CVD than absolute LDL-C or 
larger LDL-C particles [100, 120, 121, 125-127].  Furthermore, the LDL particle size has 
been found to be a significant predictor in the univariate analysis in three large studies: the 
Quebec Cardiovascular Study [126], the Harvard Physicians Health Study [128], and the 
Stanford Five City Projects [129].  Characteristics of small and dense LDL include (a) 
longer residence time in plasma and (b) enhanced susceptibility to oxidation.  These factors 
are considered as the main links to CVD.  The NCEP ATPIII [22] has identified the small 
dense LDL as an emerging cardiovascular risk factor.  
 
There exists large inter-individual variation in cholesterol content per LDL particle.  
Thus, the measures for LDL-C and LDL-Number are not equivalent.  In fact, the number of 
total and smaller LDL particles has been found as a significant and independent predictor 
of CVD risk after multivariate adjustment for lipid variables [130, 131].  Convincing 
evidences from the Cardiovascular Heart Study [130], the Women’s Health Study [132] the 
Veterans Affairs High-Density Lipoprotein Intervention Trial [5], and the Paravastatin 
Limitation of Atherosclerosis in the Coronary Arteries [133] have found that LDL-Number 
is a stronger predictor of CVD than LDL-C.  In addition, the Framingham Heart Study 
[134]  showed a parallel increase in small LDL-Number and in the number of MetS 
components in both men and women.  In addition, the number of increased small LDL 
particles was associated with the number of increased TGs and decreased HDL-C, but it 
was not reflected in the concentration of LDL-C.  Therefore, to have a reliable estimate of 
atherogenecity both the number and the size of LDL particles should be considered.   
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Insulin plays an important role in the regulation of FFA and lipoprotein profile, and 
studies have shown the association of insulin resistance with dyslipidemia.  As shown in 
Figure 8, at the level of the adipocyte, insulin resistance is considered as the initiating 
insult, which leads to increased intracellular hydrolysis of TGs and leads to release of 
FFAs into circulation [96].  Defective FFA uptake by adipocytes may also contribute to 
elevated circulating FFA levels. Increased FFA flux to the liver stimulates the assembly 
and secretion of lipoproteins [135].  Thus, fatty liver could cause atherogenic dyslipidemia 
by stimulating VLDL secretion that leads to high LDL-C and TG, small LDL particles, and 
low HDL-C [136, 137].  In addition, hyperinsulinemia enhances hepatic VLDL synthesis, 
which may directly contribute to increased plasma TG and LDL-C level.  Alternatively, 
elevated TG and LDL cholesterol levels may result from reduced insulin action on 
lipoprotein lipase in peripheral tissue [138]. 
 
 
Figure 8. A simplified model relating insulin resistance to dyslipidemia and cardiovascular disease 
[96] 
 
In addition to the changes in LDL and VLDL, diabetes patients also showed a 
significant reduction of HDL-C concentration.  It has been suggested that in type 2 diabetes 
patients, insulin resistance may be responsible for reduced HDL-C level [67, 138].  This is 
due to the increase of HDL-C degradation, which exceeded its synthesis rate.   
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In summary, increased FFA release from adipocytes or defective uptake of FFA 
into adipocytes leads to increased circulatory FFA levels.  These effects may explain the 
association between insulin resistance and dyslipidemia [96]. 
2.4.4 Hypertension 
Hypertension is one of the components of the MetS.  It has been shown that 
hypertension can promote the development of CVD [139].  Elevated blood pressure is also 
associated with obesity and glucose intolerance, and it commonly occurs in insulin 
resistant individuals.  The strength of this association, however, varies considerably from 
one population to another.  Epidemiological studies have highlighted the correlation 
between fasting insulin levels and systolic and diastolic blood pressure that is independent 
from age, weight, and serum glucose levels.  Lind et al. [93] showed that 25% of 
hypertensive subjects were insulin resistant that suggested a role of hyperinsulinemia in the 
pathogenesis of arterial blood pressure.  In addition, insulin resistance is found more 
frequently in salt-sensitive hypertensive subjects than in low salt-sensitive subjects.  
Furthermore, weight loss is associated with both blood pressure reduction and improved 
insulin sensitivity.   
 
Four main reasons may explain the association between hypertension and insulin 
resistance: (a) abnormalities in insulin-mediated vasodilatation and blood flow, (b) the role 
of increased FFAs in inhibition of vasodilatation, (c) over activity of the sympathetic 
nervous system, and (d) the role of hyperinsulinemia in increased absorption of sodium and 
water by kidney tubular cells.   
 
2.4.5 Other metabolic risk factors 
The elevation of C-reactive protein (CRP), an inflammatory cytokine, leads to the 
proinflammatory state which is commonly present in people with MetS.  Excessive adipose 
tissue leads to the release of inflammatory cytokines, which could promote an 
inflammatory state in obese individuals [5].  In fact, several studies have shown that there 
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is a significant relationship between plasma CRP and measure of adiposity and insulin 
resistance [5]. Moreover, the risk of having elevated CRP parallels the increase in the 
number of MetS components [140]. In high-risk subjects, increased physical activity is 
associated with lower sub-clinical inflammation [141].  Recent data suggest a link between 
lipoproteins and sub-clinical inflammation since hypolipidemic treatment in subjects with 
high CRP but normal LDL-C reduces CVD risk (JUPITER trial).  Furthermore, there exist 
evidences of a significant relationship between ApoB and sub clinical inflammations [141]. 
The prothrombic state is considered as another risk factor in which plasma PAI-1 
and fibrinogen have been increased.  Since high cytokine levels could lead to an increase in 
fibrinogen, an acute-phase reactant protein like CRP, the proinflammatory and prothrombic 
states are considered to be interconnected metabolically [27]. Stimulation of PAI-1 
secretion by insulin has been observed is cell culture as well as in humans following an 
intravenous insulin infusion, that suggests that hyperinsulinemia may directly inhibit 
fibrinolysis in insulin-resistant subjects [142].  High levels of VLDL can also stimulate 
PAI-1 synthesis and secretion by cultured cells.  It seems that this process is sensitive to 
the PAI-1 genotype [143]. 
 
Advancing age is another metabolic risk factor.  Several studies have shown that 
the MetS prevalence rises with advancing age [88]. Since ageing is commonly 
accompanied by a loss of muscle mass and strength as well as an increase in body fat, 
particularly in the abdomen, these abnormalities could favour the emergence of the MetS.  
Moreover, the lack of physical inactivity which occurs more commonly in elderly people 
promotes the development of obesity and insulin resistance.  By using gold standard 
methods to measure strength, insulin sensitivity, and physical activities, studies have 
shown (a) the more association of a higher strength rather than a higher muscle mass with 
insulin resistance [144], and (b) the impact of objectively measured reduced physical 
activity on the prevalence of metabolic syndrome [145].  Table 7 shows metabolic 
measurements (not included in the definition) for which additional research is required to 
explore their association with and their role in metabolic syndrome. 
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In conclusion, MetS represents a cluster of risk factors (blood pressure, obesity, 
insulin resistance, high TGs, etc.), which together increase the cardio metabolic risks 
mainly including CVD and diabetes.  Importantly, in clinical practice the MetS definition 
allows the identification of high-risk individuals for cardio-metabolic complications.  
Furthermore, since most of these risk factors are modifiable through changes in lifestyle, 
diet, and physical exercise, early identification of these subjects may allow early treatment 
of MetS and thus may reduce the burden associated with MetS.  
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Table 7. Additional metabolic measurements  
IDF [24] WHO [20, 26] 
Abnormal body fat distribution: 
General body fat distribution (DEXA) 
Central fat distribution (CT/MRI) 
Liver fat content (MRS)  
Adipose tissue biomarkers: leptin, adiponectin 
Hyperuricaemia 
 
Atherogenic dyslipidemia: (beyond TG and low HDL-C) 
ApoB (or non HDL-C), small LDL particles 
Coagulation disorders 
Insulin Resistance:(other than elevated fasting glucose) 
Fasting Insulin/proinsulin levels 
HOMA-IR 
Insulin resistance by Bergman Minimal Model 
 free fatty acids (fasting and during OGTT) 
Insulin sensitivity (hyperinsulinemic/euglycemic clamp) 
(mg/min/kg) 
 PAI-1 
Vascular dysregulation (beyond  BP) 
Measurement of endothelial dysfunction 
Microalbuminuria 
 
Proinflammatory state: 
 high sensitivity C-reactive Protein 
 inflammatory cytokines (e.g. TNF α, IL-6) 
 adiponectin plasma levels 
 
Prothrombic state: Fibrinolytic factors (PAI-1, etc.)  
Clotting factors (fibrinogen, etc.)  
 
Hormonal factors: Pituitary-adrenal axis  
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3 Literature Review of Food Quality Indices 
3.1 History of food quality indices:  
Traditional nutritional epidemiological studies have examined the association 
between diet and diseases such as CVD, obesity, and MetS.  These studies focused mostly 
on the impact of a single nutrient, dietary component, or food on the disease process [7].  
This approach has highlighted the protective effect of vegetables and the deleterious effect 
of saturated fat on coronary heart disease and cancer [146, 147].  This approach, which is 
called “reductionist” [7], presents some advantages as well as limitations [148].  Focusing 
on a single nutrient helps to understand its role in the aetiology and pathogenesis of a 
disease, but it does not allow the investigation of the overall role of dietary quality or 
dietary patterns on disease protection or susceptibility.   
According to Kant et al. [8], dietary patterns measure multiple dietary components 
as a single exposure.  In several studies, dietary patterns have been derived by either of the 
following approaches: (a) using diet indices or scores that evaluate the compliance with 
dietary guideline, or (b) using data-driven methods based on factor or cluster analysis. In 
order to investigate the relation of dietary patterns with dietary biomarkers and chronic 
disease risk, several studies considered fruit, vegetable, wholegrain, fish, and poultry 
consumptions as the components of dietary patterns, regardless of the utilized approach. 
 
The multidimensional nature of diet consumed by humans calls for the 
investigation of the association between dietary patterns and diseases as an alternative or 
complementary approach to the traditional method of investigating the effect of a single 
dietary component [147]. 
 
During the last decade, the effect of dietary patterns on all-cause mortality and 
CVD has been demonstrated through both observational and interventional studies [8].  
Dietary patterns have been shown to be stronger predictors for survival than a single 
nutrient or food component [8].  Furthermore, several clinical trials have shown that 
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changing dietary patterns lowers blood pressure more efficiently than changing a single 
dietary component [8].  However, it has been suggested that dietary-derived patterns may 
be population-specific, which could be a limitation of this approach [149].  Therefore, 
investigating the effect of overall dietary habits can be complementary to the traditional 
method of investigating the effect of a single dietary component [14].  
 
3.2 General overview on Diet Quality Scores (DQS)  
In the 20th century, nutritional over-consumption and imbalance rather than 
nutritional deficiency have been implicated in the aetiology of chronic diseases.  In fact, 
numerous studies have highlighted the strong association of the diseases including 
coronary artery diseases, stroke, diabetes, and certain forms of cancer, with the diets 
enriched in total fat, saturated fat, sodium, and cholesterol, as well as the diets low in fibre 
and complex carbohydrates.  Therefore, in 1970 the goal of dietary guidelines was to 
improve dietary patterns, nutritional status, and public health.  These guidelines propose to 
lower total and saturated fat, cholesterol, sodium and sugar, and to increase the 
consumption of fibre and complex carbohydrates as a key way to improve nutritional status 
[7].   
 
Several indices of overall diet quality or diet quality scores have been validated by 
correlating the index score to health outcome [12, 13, 15, 150-152].  Most indices are 
based on current nutritional guidelines or recommendations [153].  As listed in Table 9, at 
least 20 distinct indices of overall diet quality exist in the literature.  Among these indices, 
four are considered to be the “original ones” which include the Healthy Eating Index (HEI) 
[15], the Diet Quality Index (DQI) [12], the Healthy Diet Indicator (HDI) [154], and the 
Mediterranean Diet Score (MDS) [155].  Recently, the Mediterranean diet has received 
increasing attention because of the association of this type of diet with reduced risk of 
coronary heart disease and several forms of cancer [155-159].  The composition of these 
four scores is detailed in Table 14.  
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Compared to a monotonous diet, dietary variety also has a more beneficial effect on 
disease risk.  This fact leads to the development of a Dietary Variety Score [160-165].  In 
this index, dietary variety is calculated based on the number of different foods or food 
groups consumed over a given period.  Moreover, Kant and Thompson [150] modified this 
index and proposed to divide foods into nutrient-dense and nutrient-poor (energy-dense) 
foods in order to calculate a variety score for recommended foods.  This approach has been 
successfully used to calculate the Recommended Food Scores [9].  
 
3.2.1 Diet quality scores 
Composing an index of overall diet quality involves choosing the variables or items 
(to be included), the cut-off values, and their scoring.  This chapter is a general overview 
of the components of diet quality indices. Table 8 shows the key issues in the construction 
of diet quality scores [7]. 
 
Variables included in the index/ limitation of various indexes 
Nutrients, foods, and food groups are considered as dietary variables in diet quality 
scores.  Table 8 presents an overview of the index components of the diet quality scores, 
which are listed in Table 9.  
 
Nutrients 
Nutrients may include fat (total, saturated, polyunsaturated, etc.), cholesterol, 
complex carbohydrates, dietary fibre, protein, and alcohol.  Different units have been used 
to estimate the amount of nutrient intake. Usually, the fat intake is based on the percentage 
of energy, while micronutrients are expressed in micrograms or percentage of the 
recommended dietary allowance.  Thus, one of the criteria to obtain a good score from any 
indices is that an individual should consume at least two macronutrients. This is quite 
important because an imbalance in macronutrients consumption (fat, carbohydrates and 
protein) plays an important role in chronic diseases such as obesity and cancer [7].   
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Food items 
The inclusion of food categories in a certain index is based on the knowledge at the 
time when the index was created.  Fruit, vegetable, meat and meat products, cereals or 
grain, milk and dairy products are the main food groups that are present in most indices 
(see Table 8). But fish, legumes, nuts and soy products are only included in the more 
recent indices [11, 13]. Usually, food intake is evaluated by using the serving size or gram. 
depending on whether it is considered as a food or a nutrient respectively. Alcohol can be 
expressed by the number of glasses per day or by grams of ethanol per day. According to 
US Food and Drug Administration [166] seving size is “ a standardized amount of a food, 
such as a cup or an ounce, used in comparing similar foods. Serving sizes are stated on the 
food label. Serving size on the food label is listed as a common household measure 
followed by the equivalent metric quantity in parenthesis, for example “1/2 cup (112 g)”.  
Appendix 1 shows the serving size in all food categories. 
 
Fat 
Fat is considered as an important macronutrient and is present in most indices.  
However, various types of fat have different effects on disease risk.  For example, 
saturated fat is associated with increased CVD while higher consumption of 
monounsaturated and polyunsaturated fatty acids is associated with reduced risk of CVD 
[167-171].  Thus, the fatty acid composition of the diet is considered as an important health 
determinant.  Among the food quality indices, the DQI, HEI and HDI specifically estimate 
the amount of saturated fat intake.  
 
Fruit and vegetables 
All indices based on food items include fruits and vegetables.  In some indices, 
fruits and vegetables are considered as one group while in others they are evaluated 
separately.  The fact that all indices include these two items highlights their importance for 
a healthy diet.  
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Complex versus refined grains 
The health benefits of whole grain compared to refined grains have been shown in 
several studies [47, 172-174].  Whole grain contains fibre, as well as other components 
such as micronutrients, antioxidants and non-nutritive dietary constituents (phyto-
oestrogens in wheat bran and beta-glucans in oat), which have beneficial effects on disease 
risk [175, 176].   
 
Dairy, meat, and alcohol  
Consumption of dairy products is associated with reduced risk of several chronic 
diseases such as osteoporosis, hypertension, obesity and type 2 diabetes [177, 178].  
However, some dairy products are associated with unfavourable effects because they are 
rich in saturated fat.  Therefore, the ability of an index to distinguish between low and high 
fat dairy products is a strong advantage of that index.   
 
The consumption of meat and alcohol in moderate quantities has been associated 
with a beneficial effect, while their high consumption may lead to some adverse 
consequences. This suggests a U-shape association of health with meat and alcohol 
consumption. Consequently, categorizing these variables with a cut-point is not 
appropriate.  The best approach is to apply a recommended range for their intake amounts 
since insufficient and excessive intakes are not rewarded.  
 
Cut points and scoring  
The constitution of a diet quality index required that foods and nutrients become 
quantified accurately.  Various methods have been used to achieve this goal.  Using a cut 
off value seems to be the most straightforward method.  Some indices (e.g. MDS) use the 
median intake for each variable independently of the recommended intake.  One problem 
with this approach is that the medians will be different among various populations. 
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Furthermore, this does not reflect whether participants have healthy intakes of each 
variable.  However, the advantage of this method is that half of the subjects will score 
positively while the other half will score negatively for each item.   
 
Other indices are based on dietary guidelines with specific cut-off values for each 
variable.  However, this method does not discriminate between various intake levels.  To 
address this issue, some indices (e.g. DQI) include lower, intermediate, and upper 
boundaries.  Other indices (e.g. HEI) score each item proportionally to the dietary 
guideline recommendation.  In these indices, the degree to which an individual satisfies the 
dietary guideline recommendation is reflected in the total score.   
 
Energy intake 
Individuals who have high levels of energy intake may consume more food 
servings and food groups, and thus they can meet the dietary guidelines more easily in 
spite of unbalanced diets (e.g. high fat).  Some indices have addressed this issue by scoring 
the number of servings and energy intake levels based on sex and age.  These indices better 
reflect whether the diet is balanced or not.  
 
Relative contribution of the individual index components to the score 
The relative contribution of different items to the total score is another important 
but not frequently asked question.  In most indices, all variables contribute equally.   
 
3.3 Different approaches to evaluate diet quality 
There are different approaches to evaluate diet quality [7] that are categorized 
based on: 1) dietary guidelines, 2) the Mediterranean diet, 3) food consumption, 4) nutrient 
intake, and 5) variety.  Table 9 shows the most frequently used indices according to these 
categories.  
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Table 8. Overview of the attributes included in the existing diet quality scores [7]  
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Table 9.Overview of existing diet quality scores and studies in which they have been used 
and/ or evaluated [7] 
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3.3.1 Approaches Based on Dietary Guidelines 
3.3.1.1 Healthy Eating Index (HEI)  
The focuses of earlier research were exclusively on nutrients by using the mean 
adequacy ratio of the diet or percentages of Recommended Dietary Allowances to estimate 
diet intake.  In 1990, for the first time Patterson et al. proposed a diet quality index based 
on the US dietary guidelines [179].  In 1995, Kennedy et al. [15] expanded this index and 
provided a more comprehensive set of indicators for diet quality that led to the 
development of the HEI. 
 
Overall structure of Healthy Eating Index 
As shown in Table 10 [15], the HEI contains 10 components: grains, vegetables, 
fruits, milk, meat, total fat, saturated fat, cholesterol, sodium and variety.  The score for 
each component ranges from 0 to 10, and the total diet score from 0 to 100.  The serving 
size for each food group is based on the food guide pyramid [180].  The first five 
components (grain, vegetables, fruits, meat, and milk products) are based on serving sizes 
[180]. Legumes are assigned to the meat group up to the maximum score, and any 
additional intake is assigned to the vegetable group. On the other hand, soy products, 
which are considered as a meat substitute, are always assigned to the meat group.  
Components 6 and 7 are based on total and saturated fat consumption and are expressed as 
a percentage of total food and energy intake, respectively.  Component 8 and 9 are based 
on cholesterol and sodium intake, and component 10 shows the amount of variety of the 
subject’s diet.   
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Table 10. Components of Healthy Eating Index (HEI-90) [15]  
Components Range of score Criteria for score 10 Criteria for score 0 
1) Grain 0-10 6-11 servings 0 
2) Vegetables 0-10 3-5 servings 0 
3) Fruits 0-10 2-4 servings 0 
4) Milk 0-10 2-3 servings 0 
5) Meat 0-10 2-3 servings 0 
6) Total fat 0-10  30% energy  45% energy 
7) Saturated fat 0-10 < 10% energy  15% energy 
8) Cholesterol  0-10 < 300 mg  450 mg 
9) Sodium 0-10 < 2 400 mg  4 800 mg 
10) Variety 0-10 
16 different kinds of 
food items over 3 day 
period 
 6 food items over 3 
days 
 
Index scoring for components 1-5 
Table 11 shows the recommended number of servings per day and per total calorie 
ingested, and thus it takes into account the total energy intake.  A score of 10 belongs to an 
individual who consumed the recommended number of servings, while a score of 0 is 
assigned to an individual who did not have any servings for that certain item.  In between, 
the score is calculated proportionally to the ingested amount of component.  For example, 
a 40 years old woman with an energy intake of 2200 kcal/day should consume four 
servings of vegetables for a score of 10 while a 0 is assigned if she does not consume any 
vegetable at all.  The consumption of 2 servings will give her a score of 5.  For each 
component, when the optimum number of servings is achieved, neither further credits are 
given nor are any points deducted for additional servings.  
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Index scoring for components 6-10 
Scoring of these components is based on their portion of total energy intake.  A 
scored of 10 is assigned when total fat and saturated fat intakes represent less than 30% 
and 10% of total energy intake, respectively. A score of 0 is assigned when total and 
saturated fat intakes represent  45% and 15%, respectively.  Cholesterol and sodium 
intakes are calculated based on milligrams of intake.  A score of 10 is assigned when 
cholesterol and sodium intakes are less than 300 mg and 2 400 mg, respectively.  A score 
of 0 is assigned when cholesterol and sodium intakes are  450 mg and 4 800 mg, 
respectively.  These upper limits for total fat, saturated fat, cholesterol and sodium were 
determined from the 1989-1990 Continuing Survey of Food Intake by Individuals (CSFII) 
[181].  Both the UDSA Food Guide Pyramid [180] and the National Academy of Science’s 
diet and health report have emphasized the role of dietary variety in a healthy diet [182],  
but few indices include this component [183, 184].  A score of 10 is obtained when 16 or 
more different foods are consumed during the 3-day study period, and a score of 0 is 
considered if 6 or less distinct foods are eaten.   
 
Table 11. Recommended numbers of servings per day per energy intake [15] 
 
3.3.1.2 HEI adapted for Canadian 
The HEI has been adapted for the Canadian population by Shatenstein et al. [18] 
based on Canada’s Food Guide for Healthy Eating and Nutrition Recommendations for 
Canadians [185].  The index was validated against a self-administered semi-quantitative 
FFQ, which was designed in French and English based on the Block National Cancer 
Institute Health Habits and History Questionnaire to capture usual food consumption 
K calories Grains Vegetable Fruits Milk Meat 
1 600 6 3 2 2 2 
2 200 9 4 3 2 2.4 
2 800 11 5 4 2 2.8 
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among adults.  The FFQ was pre-tested in a pilot study and was administered by mail to a 
random sample of 248 Quebecers, 106 men (43%) and 142 women (57%), aged 18-82 
years within the Montréal area. A subgroup of 94 individuals gave four non-consecutive 1-
day food records for validation of the FFQ. 
 
As shown in Table 12 the HEI, which was adapted for Canadian population [18], 
includes nine components. Each component is worth 10 points except for the vegetable and 
fruit sub-scores, which are worth 20 points each.  Dietary variety was also modified, 
because in the original HEI the variety sub-score counted the total number of different 
foods eaten during the 3 days, while the FFQ provided food intakes over a 12-month 
period.  Therefore, the variety sub-score was made more reflective for Canada’s Food 
Guide for Healthy Eating recommendation [185] by using a variant of the Dietary 
Diversity Score [151].  The Canadian HEI has a maximum score of 100 points. 
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Table 12.  Criteria used in Canadian adaptation of the Healthy Eating Index (HEI-Ca) [18]  
Components a 
Score 
range 
(points) 
Criteria for maximum score  
by sex and age b 
Criteria for 
minimum score Female Male 
18-49 >50 18-49 >50 
Grain products 
(serving) 0-10 9 6 12 9 0 serving 
Vegetables and fruits 
(serving) 0-20 7 5 10 7 0 serving 
Milk products 
(serving) 0-10 2 2 2 2 0 serving 
Meat and meat 
alternatives (serving) 0-10 2.5 2 3 2.5 0 serving 
Total fat intake (%) 0-10 < 30% total energy from fat  45% total energy from fat 
Saturated fat intake 
(%) 0-10 
< 10% total energy from 
saturated fat 
 15% total energy 
from saturated fat 
Cholesterol intake 
(mg/day) 0-10  300 mg cholesterol  450 mg cholesterol 
Sodium intake 
(mg/day) 0-10  2400 mg sodium  4800 mg sodium 
Dietary Variety 0-10  1 portion from each of four 4 groups of CFGHE 
<1 serving from each 
of 4 food groups of 
CFGHE 
Adapted from [18] 
a The first four components are based on Canada’s Food Guide for Healthy Eating (CFGHE) [185]; 
evaluation considers daily intakes 
b Number of servings is based on approximate energy intakes (2200 kcal/day for women aged 18-49y, 1600 
kcal/day for women > 50 y, 2800 kcal /day for men aged 18-49 and 2200 kcal/day for men > 50 y) adopted 
from Bowman and colleagues [186] 
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3.3.1.3 The HEI-05 and the HEI 2005 
Recently, Gao et al. [187] and Guenther [188, 189] updated the original HEI.  As 
shown in Table 13, the only difference between the HEI-05 and the original HEI is that 
three activity levels (sedentary, moderately and active) have been assigned for energy 
requirements.  In addition, dietary variety is the sum of different foods consumed during 
the past 12 months instead of the past 3 days. 
  
Similarly, there are two major differences between the HEI-2005 and the original 
HEI.  First, the scoring system is based on the new food intake patterns developed 
specifically for the My Pyramid Food Guidance System [190].  Second, the standard for 
each component is based on the energy density approach.  Thus, the food group standards 
are expressed per 1000 kcal while standards for nutrients and discretionary energy are 
based on percentage of total energy [191]. 
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3.3.1.4 Alternate Healthy Eating Index (AHEI) 
In 2002, McCullough et al. created the AHEI [9] by using dietary questionnaires 
from 38615 men of the Health Professional’s follow-up study and 67271 women of the 
Nurses Health Study. The objective was to generate an index that would better predict 
chronic disease risk and better identify food choices and macronutrient associated with 
chronic disease risk [9, 192].  A major chronic disease was defined as the initial occurrence 
of CVD, cancer or non-traumatic death during 8-12 years of follow-up.  They found an 
association between the AHEI score and reduced chronic disease risk.  The investigators 
attributed this finding to the ability of the AHEI to capture certain dietary choices (e.g. 
white versus red meat consumption and the type of fat consumed).  Moreover, the 
incorporation of n-3 fatty acids into the score might have improved the sensitivity of this 
score to CVD.  
 
As shown in Table 14, the index contains 9 components: vegetables, fruits, nuts 
and soy, the ratio of white to red meat, cereal fibre, trans fat, the ratio of polyunsaturated to 
saturated fat, alcohol and duration of multivitamin used. A sub-score of 0-10 is allocated to 
each of the first eight components, where 10 represented a healthy diet and 0 indicated a 
poor diet quality. Intermediate intakes are calculated proportionally to the consumed 
amount (between 0 and 10).  The consumed multivitamin is dichotomous and 2.5 and 7.5 
points are assigned to non-users and users, respectively.  The sum of all components can 
vary from 2.5 (poor) to 87.5 (best).  
 
3.3.1.5 Diet Quality Index (DQI) 
The DQI was developed by Patterson et al. [12] in 1994 to measure overall diet 
quality and its role in chronic diseases.  The index is based on the US dietary 
recommendation while the serving size for each food group is based on the Diet and Health 
guidelines [193]. As shown in Table 14, the DQI is composed of eight components, 
namely total fat, saturated fat and cholesterol, fruits, vegetables, grains and legumes, 
protein, sodium and calcium.  The scoring weight of each component is based on its 
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association with disease risks.  Each component is scored from 0 to 2, where 0 represents 
an excellent diet and is assigned to individuals who meet dietary goals, 1 represents a fair 
diet, and 2 is assigned to individuals with poor diets.  Accordingly, the total score ranges 
from 0 (excellent diet) to 16 (poor diet).  It is believed that the index’s score reflects diet 
quality.  However, substantial misclassification can occur because a single nutrient or food 
is used as an indicator of diet quality. 
 
3.3.1.6 Diet Quality Index Revised (DQI-R)  
The DQI was revised by Haines et al. in 1999 [151].  The revised index reflects 
improved methods to estimate fruit, vegetable and grain servings, and it integrates the 
measures of diet variety and proportionality.  The DQI-R contains 10 components and each 
one contributes to 10 points for a total of 100 (Table 14).  Scoring of fruit, vegetable, and 
grain is based on the percentage of the recommended servings.  The iron and calcium 
intakes are scored based on RDA and Adequate Intake Value, respectively.  They are 
considered as continuous variables ranging in 0-100%.  The dietary diversity score was 
developed to reflect differences in consumption across 23 food group categories, which 
were chosen to capture food diversity.  Dietary moderation includes 4 components, namely 
added sugars, discretionary fat, sodium and alcohol [151].  The relative levels of total fat, 
saturated fat and cholesterol have not been included in the score since they all have been 
considered as independent components in DQI-R [54].  In this index, a low score is 
assigned when dietary recommendations are not met, while higher score reflects high 
quality diet.  The points are assigned as follow: 10 points when recommendations are meet, 
5 points for those within 30% of the recommendations, and 0 points for those 30% above 
upper threshold.   
 
3.3.1.7 Diet Quality Index International (DQI-I) 
This index was created by Kim et al. [194] to make cross-national comparison of 
diet quality between China and USA.  It has been found to be an appropriate index for 
investigating diet quality across countries and for global monitoring of diet healthfulness.  
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The index is composed of four major components, namely variety, adequacy, moderation 
and overall balance, which represent the major aspects of a healthy diet.  The selection 
component and the scoring system are provided by using the current worldwide and 
individual dietary guidelines [195, 196], the food guide pyramid [180], and several dietary 
indices [12, 15, 151, 197].   
 
Variety is categorized into two different groups: overall variety and variety of 
protein sources [192, 194].  The overall variety score is based on the inclusion of at least 
one serving per day from each of the five food groups: meat/poultry/fish, eggs, 
dairy/beans, grains, and fruits and vegetables.  The variety of protein sources is evaluated 
among the following 6 items: meat, poultry, fish, dairy, beans and eggs.  The total variety 
score is obtained by adding the overall variety score (in the range of 0-15) and the variety 
score of protein sources (in the range of 0-5) [58].  The adequacy sub-score (in the range of 
0-40) is determined from the consumption of a sufficient amount of the following dietary 
elements, namely vegetables, fruits, grains, fibre, protein, iron, calcium, and vitamin C, to 
maintain a healthy diet [192, 194].  The recommended intake of fruits, vegetables, grain 
and fibre is adjusted with the total energy intake according to age and gender.  
 
The moderation sub-score (in the range 0-30) evaluates the intake of specific 
elements (total fat, saturated fat, cholesterol, sodium and empty calorie food) associated 
with an increase risk of chronic diseases.  Accordingly, the maximum score is obtained 
with low intake of these elements.  The last component of the DQI-I is the overall balance 
(in the range 0-10), which represents the proportion of macronutrients (the proportion is 
denoted by “carbohydrate: protein: fat”) and the fatty acid composition that contribute to 
energy intake.  
 
3.3.1.8 Healthy Diet Indicator (HDI) 
Hujibregts et al. [154] created the HDI to investigate the association of dietary 
pattern and mortality.  They used the dietary history of 3045 men aged 50-70 from five 
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cohorts in Finland, Netherlands and Italy in 1970.  After 20 years follow-up, they verified 
the vital status and calculated the mortality rate.  In this dietary survey method, they 
estimated the usual food consumption pattern during 6-12 months, and they used the WHO 
guidelines for the prevention of chronic diseases [154]. 
 
As shown in Table 14, the HDI contains 9 components including saturated fatty 
acids, polyunsaturated fatty acids, protein, complex carbohydrate, dietary fibre, fruits and 
vegetables, pulses/nuts/seeds, monosaccharide/disaccharides, and cholesterol.  However, 
the index excludes salt, alcohol [154, 192], total fat, and carbohydrate in order to avoid 
overlap.  A score of 1 is assigned to intake within the recommended range of WHO 
guidelines [195]; Otherwise, a score of 0 is assigned.  The summation of the 9 individual 
scores gives a final score, which varies from 0 to 9 [154, 192].  Studies have shown that 
the HDI is a strong tool for assessing diet quality and for evaluating future adverse health 
events [192]. 
 
3.3.1.9 Dietary Guideline Index (DGI) 
The DGI was created by Harnack et al. [153]  using data from 34 708 women of the 
Iowa Women’s Health Study, a population-based cohort of postmenopausal women for 
whom diet was assessed in relation to cancer occurrence. The components and the 
corresponding scores of the DGI are shown in Table 14. This index contains 9 components 
in which the maximum and minimum scores of 2 and 0, respectively, could be assigned to 
each component according to its compliance with the dietary guidelines.  Therefore, a total 
score of 18 across the 9 components defines full compliance with guideline whereas the 
total score of 0 indicates non-compliances.  
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3.3.2 Based on Mediterranean diet   
3.3.2.1 Mediterranean diet score (MDS)  
The MDS was developed by Trichopoulou et al. [155] in 1995 by using 91 men and 
women, who were over 70 years old and from three rural Greek villages.  The goal was to 
investigate the influence of a specific dietary pattern on overall survival.  The dietary 
habits were assessed with a validated extensive semi-quantitative food frequency 
questionnaire.  The study showed that the role of overall dietary pattern in health is more 
important than individual nutritional components, and thus it highlighted the benefits of 
Mediterranean diet to the health and longevity of this population.  As shown in Table 14, 
this index includes eight components: high consumption of vegetables, legumes, fruits, 
cereals (including breads, potatoes, starchy roots but excluding sugar and syrup), low 
consumption of meat and meat products, milk and dairy products, a high ratio of 
monounsaturated to saturated fat, and moderate alcohol consumption [155].  This index 
uses a median value as the cut point for each sex.  A score of 0 and 1 is assigned to each 
component if the consumed amount is above and below the median, respectively.  
Therefore, the total score varies from 0 (poor diet) to 8 (excellent diet) [155].  The original 
MDS has been modified and used in several studies related to health outcomes.  
 
3.3.2.2 Mediterranean Diet Quality Index 
The MDQI has been used in two studies [198, 199] to set up the DQI and assess the 
dietary habits of Mediterranean southern France.  As shown in Table 14, this index 
includes 7 components: saturated fat, cholesterol, meats, olive oil, fish (including white 
and fatty fish), cereals (including breads, pastas and rice as well as breakfast cereals), and 
fruit and vegetables. The number of cigarettes per day is not always included in the 
calculation of the index.  For example, Gerber et al. [199] included the number of 
cigarettes in their study while Scali et al. [198] did not.  Each nutrient or food group is 
divided into 3 sub-scores (0, 1 and 2) according to the recommendation guideline.  These 
sub-scores are summed up for each subject that lead to a total score in the ranges 0-16 and 
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0-14 depending on whether  the number of cigarettes are included or not [198, 199].  In 
both indices, a low score indicates a better diet.  
  
3.3.2.3 MDS + Fish 
This index has been developed by Trichopoulou et al. [155] in 2003.  It contains 14 
components, namely potatoes, vegetables, legumes, fruits and nuts, dairy products, cereals, 
meat, fish, egg, monounsaturated fat (mainly olive oil), polyunsaturated fat (vegetable-
seeds oil), saturated fat and margarines, sugar and sweets, and non-alcoholic beverages.  
This index was modified by Knoops et al. [11] in 2004 to include only 8 components, 
namely legumes/nuts/seeds, grains, fruits, vegetables and potatoes, meat and meat 
products, dairy products, fish, and the ratio of monounsaturated to saturated fat.  In both 
studies, the cut-off point is based on the median and is specific for each sex.   
 
3.3.3 Other indices adapted from MDS 
There exist multiple modified forms of the MDS [11, 200-202], and each form has 
its own components and scoring system.  In addition, in 2007 the Mediterranean Adequacy 
Index (MAI) has been reported [203], in which 18 food groups and the specific score 
calculations were presented.  
 
3.3.3.1 Food consumption 
Other less frequently used indices have been developed based on food groups. 
These indices include the Food Based Quality Index (FBQI), the Healthy Food Index 
(HFI), and the Food Pyramid Index (FPI).  The FBQI investigates the relationship between 
dietary characteristics and nutrient density of diets in accordance with the guidelines and 
food variety [204].  The HFI is based on dietary guidelines for a healthy diet and contains 
6 components (butter, margarine, animal fat, vegetables, coarse bread, and fruit).  Its score 
varies from 0 (poor diet) to 4 (excellent diet) [205].  Massari et al. developed the FPI to 
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examine the association between coronary heart disease risk factors and eating pattern.  
This index is an aggregated dietary index, which compares the ratio of fatty food to items 
with negligible fat contents [206].  
 
3.3.3.2 Nutrient based scores 
The Nutrient Adequacy Ratio (NAR) is a nutrient based index developed by 
Madden and Yoder in 1972.  The NAR is the ratio of a nutrient intake relative to its RDA.  
The mean adequacy ratio (MAR) is computed by averaging the sum of the NAR.  These 
indices have been used in several studies to evaluate diet quality scores [207].  Table 14 
summarizes the components and scoring systems of the existing diet indices. 
 
 
Clinical outcome of HEI 
The HEI is the most frequently used index and has been validated in multiple 
studies.  Kennedy et al. [15] showed that the HEI is a useful tool to estimate the overall 
diet pattern.  Furthermore, the index sub-scores correlate positively with the consumption 
of most nutrients.  The index scores correlate positively with biomarkers such as alpha- 
and beta-carotene, vitamin C, folate, and fibre [208, 209].  However, in spite of its strong 
association with individual diet components, the HEI was not associated with cancer risk 
both in men and women [210].   
Studies have shown that the Canadian HEI adequately discriminates the overall diet 
quality based on dietary data from Food frequency questionnaire, and suggests examining 
the sub-scores within and between quartiles to improve diet quality [18].  More recently, 
the HEI was found to be a predictor of chronic disease [16]. Furthermore, a lower HEI 
score has been shown to be associated with overweight state and obesity [17].   Table 15 
illustrates the association of dietary indices and scores with nutrient adequacy, biomarkers 
of health, disease outcome, and mortality.  
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4 Rational 
 
The presence of MetS significantly increases the risk of developing type 2 diabetes 
and CVD. Thus, identifying factors that promote the development of MetS or its 
components would likely diminish the risk of CVD and diabetes.  Obesity is an important 
component of MetS.  Furthermore, overweight or obese subjects are at increased risk of 
diabetes and CVD. In addition, overweighting and obesity have been shown to be 
significantly correlated with MetS, unlike normal BMI [44, 61, 62]. 
The association of HEI with obesity, chronic diseases, and some metabolic 
disorders has been validated by several studies [10, 16, 17, 187, 189, 209]. Importantly, the 
HEI has been validated for the Canadian population by another study [18]. Therefore, we 
determined that HEI was the most appropriate index to be used in our study. 
 
Numerous studies have suggested that lifestyle including dietary patterns plays an 
important role in MetS.  A few studies have shown a significant correlation of Diet 
Diversity Score with Mets in Tehranian adults [14].  Furthermore, another study has used 
HEI to evaluate the relationship of MetS with diet and physical activity in the US 
adolescents [212]. This study showed that a higher HEI score was significantly associated 
with a lower prevalence of MetS [212]. 
 
The objective of our study was to investigate the relationship of diet quality with 
MetS and its components. Our study included a population of overweight and obese 
postmenopausal women, who where at higher risks of metabolic complications due to their 
postmenopausal state. 
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5 Research design and method 
5.1 Subjects 
In this research, the samples were drawn from 137 non-diabetic, sedentary, and 
overweight or obese postmenopausal women aged 45-70 years, who had been recruited for 
the Montreal Ottawa New Emerging Team (MONET) Weight-loss Weight-Regain 
(WLWR) study.  The recruitment of healthy, overweight, and obese postmenopausal 
women for this study was done by newspaper advertisement in the Montréal area from 
May 2003 to February 2006. 
 
The study was approved by the Research Ethics Board - Faculty of Medicine 
(Comité d'éthique de la recherche de la Faculté de medicine, CÉRFM), Université de 
Montréal, and all participants gave an informed written consent before participation in 
accordance with the ethical guidelines of the Université de Montréal Research Ethics 
Committee.  After reading and signing the consent form, each participant was invited to 
the Metabolic Unit of the Nutrition department for a series of tests.  The women who were 
included in the study met the following criteria: 
1) Cessation of menstruation for more than 1 year, and follicle-stimulating hormone 
level  30 U/L 
2) No use of hormone replacement therapy (except for L-Thyroxine T4 (Synthroid®) 
at stable dosage with optimal plasma TSH levels) 
3) Sedentary (less than 2 h /week of structured exercise) 
4) Non-smoker 
5) Free of known inflammatory diseases and cancer 
6) Body mass index  27 kg/m2  
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Based on physical examination and biological testing, it was shown that all 
participants had no history or evidence of:  
1) Cardiovascular disease, peripheral vascular disease, uncontrolled thyroid disease, 
and stroke 
2) Diabetes (fasting plasma glucose > 7.0mmol/L, and 2 h after a 75-gram OGTT 
plasma glucose > 11.0 mmol/L) 
3) Orthopaedic limitations  
4) Medication that could affect cardiovascular function and/or metabolism 
5)  Use of hormone replacement therapy, oestrogen, narcoleptics, steroids, lipid-
lowering, and antihypertensive agents 
6) Dyslipidemia or hypertension requiring immediate medical intervention (total 
cholesterol > 8.00 mmol/L, triglyceride > 4.5 mmol/L, and blood pressure 
> 160/100 mm Hg) 
7) History of alcohol or drug abuse  
8) Abnormal blood laboratory values (creatinine > 135 μmol/L, and haemoglobin 
< 120 g/L)  
9) Use of (a) drugs or medications to stimulate weight loss, (b) psychoactive drugs, 
and (c) adrenergic agonists  
10) Reported body weight fluctuation beyond 2 kg in the last 3 months  
5.2 Study Design 
In this study, two hundred fifty two participants were invited to the Metabolic Unit 
of Nutrition department, at 7:30 a.m. in the fasting state, for the inclusion protocol 
including OGTT, fasting blood samples, and physical examination.  One hundred thirty 
seven participants, who were qualified for the inclusion protocol, went through a 4-week 
weight stabilization period (± 2 kg) that was verified by weekly weighting at the Metabolic 
Unit.  Within the 4 consecutive weeks, patients underwent a series of tests including 
euglycemic-hyperinsulinemic clamp (EHC), body composition using DXA and CT-scan 
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for visceral adiposity, aerobic capacity, resting energy expenditure (REE), total energy 
expenditure (TEE) using doubly labelled water, psychosocial and socio-demographic 
questionnaires, and 3-day food record.  All these tests were done at the inception of the 6-
month weight-loss study by using caloric restriction with or without a resistance-training 
program.  
 
Among the 137 subjects who were tested at baseline, 88 subjects had the complete 
data for the variables of interest (food intake, blood pressure, lipid profile, body 
composition, and glucose homeostasis) and hence were included in the analysis. 
 
5.3 Methods 
5.3.1 Blood samples 
After an overnight fast (12 h), venous blood samples were collected for the 
measurements of total cholesterol, HDL-C, triglycerides, ApoB, and insulin.  LDL–
cholesterol was calculated by using the Friedewald equation [213].  All samples were 
analyzed on the day of collection by using the COBAS INTEGRA 400 (Roche Diagnostic, 
Montréal, Canada) except for insulin and ApoB, which were kept at -80 C until the 
analyses were performed.  
 
Fasting insulin level was determined in duplicate by using radioimmunoassay with 
human insulin serving as the standard (Linco Research Inc, St-Charles, MO).  The ApoB 
was assessed by using immunophelometry on an image analyzer (Beckman-Coulter, 
Villepinte, France). Because more than 90% of total ApoB (up to 13 mmol/L of 
triglyceride) was bound to LDL-C particles, we used the LDL-C/ApoB ratio to estimate 
the size of LDL-C particles [214]. 
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5.3.2 Insulin sensitivity measurement and estimation  
5.3.2.1 Euglycemic-hyperinsulinemic clamp 
 
The aim of this test is to measure insulin sensitivity in peripheral tissues, which 
mainly include adipose tissue and muscle. To ensure appropriate glycogen concentration, 
the test was preceded by 3 days of dietary and exercise advices.  The suggested diet 
provided more than 250 g of carbohydrates per day.  Furthermore, the subjects were asked 
to refrain from any physical activities for 48 h prior to the test. After a 12-h overnight 
fasting, the study began at 7:30 a.m. according to the procedure described by DeFronzo et 
al [113]. The cannulation of an antecubital vein was done on each arm, one for plasma 
collection and the other for insulin infusion.  The cannulation for plasma collection was 
done as close to the hand as possible. The arm was warmed up to 60° C in order to produce 
arterialized blood for sampling. Three blood samples were taken over a 40 min time 
interval to determine the basal plasma glucose and insulin values. After a priming dose, 
insulin infusion was kept constant (75 μU/m2/min; Actrapid®, Novo-Nordisk, Toronto, 
Canada) for 180 min.  This insulin level was chosen to ensure the complete suppression of 
hepatic glucose output. 
 
Plasma glucose was measured every 5-10 min by using a glucose analyzer 
(Beckman Instruments, Fullerton, CA) and was maintained at the fasting level with 
variable infusion rate of 20% dextrose with 20 meq/L of potassium. Infusion of glucose 
and insulin was initiated simultaneously. Efforts were made to keep the plasma glucose 
and the 20% dextrose infusion stable during the last 30 min of the test (steady state).  The 
fasting and steady state plasma glucose and insulin levels were determined by using the 
mean of the three values, which were taken over a 40 min time interval as mentioned 
above. The amount of glucose infused to maintain euglycemia during the last 30 min of the 
clamp (glucose disposal), was proportional to insulin sensitivity.  The insulin sensitivity 
was expressed by using the following formula: glucose infusion rate (GIR) in the last 30 
min of the clamp expressed as milligram per min per kilogram fat-free mass (mg/min/kg 
FFM, also known as MMT3). 
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5.3.2.2 Oral glucose tolerance test (OGTT) 
According to the Canadian Diabetes Association guidelines [215], after a 12-h fast, 
a 2-h 75-g OGTT was performed.  Blood samples were collected through a venous catheter 
from an antecubital vein in vacutainer tubes containing EDTA (SST gel and Clot activator) 
at 0, 30, 60, 90, and 120 min time instants. The plasma glucose and insulin levels were 
measured as described in the clamp test.  
 
5.3.2.3  Fasting surrogate indices of insulin sensitivity 
The most widely used index for estimating insulin resistance is the Homeostasis 
Model Assessment - Insulin Resistance (HOMA-IR), which utilizes the fasting plasma 
glucose and insulin values.  This index was calculated according to the formula of 
Mathews et al. (Fasting insulin (μM/ml) × fasting glucose (mmol/L)/22.5) [216].  
 
5.3.3 Blood pressure  
Sitting blood pressure, which was measured by using Dinamap automatic machine 
(Welch, Allyn Inc), was determined by taking the average of the last 4 of the overall 5 
readings (at the rate of 1 reading per min) in the left arm after the subject rested quietly for 
10 min. 
 
5.3.4 Body composition 
Body weight was measured by using Dual-energy X–ray Absorptiometry (DXA) 
(Perspective Enterprises, Portage, MI, USA), which is described below. Moreover, the 
height was measured with a wall stadiometer.  The values obtained were used to calculate 
BMI (body weight (kg)/height (m2)) [217].  Waist and hip circumferences were measured 
with a non-extendable linear tape measure according to the standard method [218]. 
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5.3.4.1 Dual-energy X–ray Absorptiometry (DXA) 
Regional and whole body compositions (body weight, fat free mass, fat mass, 
peripheral fat mass, central fat mass, and percentage of fat mass) were measured by using 
DXA, which was calibrated daily by using a standardized procedure. The central body 
region was defined based on the following boundaries: (a) a horizontal line below the chin, 
(b) two vertical lines passing through the arm sockets along the edges of the ribs 
(separating the arms from the body), and (c) two diagonal lines beginning on the side of 
the trunk on top of the pelvis bone and meeting at the end of the soft tissue between the 
legs.  The amount of peripheral fat tissue was determined by adding the quantity of fat, 
which was present in arms and legs and was outside the boundaries mentioned above.  The 
same strategy was used to determine the amounts of peripheral and central lean body 
masses. 
 
5.3.4.2 Computed tomography (CT) 
Visceral adipose tissue (VAT), subcutaneous adipose tissue, total abdominal fat, 
and thigh subcutaneous fat were all measured by using a GE high-speed advantage CT 
scanner (General Electric Medical System, Milwaukee, WI, USA).  The participants were 
examined while they were remaining in the supine position with both arms stretched above 
their head. The position of scan was established at the L4/L5 level according to a scout 
image of the body. The VAT area was quantified by delineating the intra-abdominal cavity 
at the most internal aspect of the abdominal and oblique muscle wall surrounding the 
cavity, and the posterior aspect of the vertebral body.  The cross-sectional areas of adipose 
tissue were highlighted and computed by attenuation ranging from -190 to -30 Hounsfield 
units, and by using a commercially available software (GE Medical System) [219]. 
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5.3.5 Energy metabolism 
5.3.5.1 Resting Energy Expenditure (REE) 
After a 12-h fast, the REE was measured by using indirect calorimetry. The 
concentrations of CO2 and O2 were measured by using the ventilated hood technique with a 
Sensor Medic Delta Track II (Datex-Ohmeda, Helsinki, Finland).  The gas concentrations 
were used to determine the 24 h REE by using Weir’s equation [220].  Measurements were 
performed while the subjects were lying in a supine position and were avoiding speaking, 
sleeping, and moving for 40 min.  The first 10 min time interval was considered as the 
acclimatizing period and the last 30 min was used for the analyses. Before every 
measurement, the gas analyzers were calibrated for pressure and gas concentrations. 
 
5.3.5.2  Total Energy Expenditure (TEE) 
Daily TEE was determined from doubly labelled water (DLW) over a 10-day 
period [221]. The DLW experiments generated 5 urine samples per study as follow: one 
pre-dose sample was collected at baseline; two samples were collected (16-24 h later) after 
the 2H218O dose had initially equilibrated in the body, and two more samples were 
collected 10 days later.  All samples were measured in triplicate for 18O-water and 2H-
water.  An Isoprime Stable Isotope Ratio Mass Spectrometer was connected to a 
Multiflow-Bio module for Isoprime, and a Gilson 222XL Autosampler (GV instruments, 
Manchester, UK) was used to make daily energy expenditure measurements.  Data 
processing was performed by using the Mass Lynx 3.6 software. Stability tests were 
performed each day before sample’s determination and gave a standard deviation of 
0.026% for deuterium and a standard deviation of 0.004% for 18O. 
 
5.3.5.3 Physical activity energy expenditure (PAEE)   
PAEE was calculated from the following equation: PAEE = (TEE × 0.90) - REE 
[221], while assuming that the thermic effect of food was 10% of TEE [222]. 
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5.3.6 Quantitative and qualitative food intake assessment 
The Healthy Eating Index (HEI) was used to assess diet quality. This index was 
chosen because it was among the most frequently used and the best validated food quality 
scores in the literature. We used the Canadian HEI (HEI-Ca), which had been previously 
adapted for the Canadian population by Shatenstein et al. [18]. The HEI-Ca contains 9 
components based on Canadian Food Guide 1997 [185]  as described before.  Briefly, this 
index includes: 
1) Number of servings of the 4 major food groups: grain products, vegetables and 
fruits, milk products, and meat and alternatives,  
2) 3 components reflecting fat intake: total fat, saturated fat, and cholesterol, 
3) 1 component addressing sodium intake, and 
4) 1 component addressing the variety of food consumed.  
 
Food servings and nutrient intakes were assessed with a 3-day food record at baseline. 
Studies have shown that some subjects underreported some of the food categories when 
using a 3-day food record [223]. However, the 3-day food record performed reasonably 
well compared to the double labelled water (DLW), which is the gold standard method to 
evaluate energy intake. Therefore, the 3-day food record can be used to evaluate food 
intake [223]. 
 
Subjects were instructed by a registered dietician to keep a record of their food intakes, 
including condiments and beverages, over two weekdays and one weekend day while 
maintaining their usual habits. Each food record was reviewed by the dietician, while being 
with the subject, to complete missing information. The dietician evaluated the serving size 
of each food eaten by the subject. She divided the amount of foods (gram) or beverages 
(milliliter) consumed by the subjects by the amount of one serving size as defined in the 
Canadian Food Guide (Appendix 1). Analyses were conducted with the Food Processor 
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SQL program (Food Processor SQL Edition, version 9.6.2, 2004, ESHA Research, Salem, 
OR, USA), by using the 2001 Canadian Nutrient Data File [224] and the US Department of 
Agriculture (USDA) databases [179]. The data entry of the food records was done by a 
registered dietician and was independently verified by a second dietician.  Discrepancies 
between the two registered dieticians were discussed and modifications were made 
according to their mutual decision.  The mean intake values (over the three day period) of 
food group servings, total and saturated fat, cholesterol, and sodium were calculated for 
each subject.   
 
5.3.7 Cardio-metabolic assessment 
5.3.7.1 Metabolic syndrome definitions 
To investigate the relationship between HEI and cardio metabolic characteristics, 
we have chosen the most widely used definition of the MetS in North America, namely the 
NCEP ATPIII (Table 1). 
 
5.3.7.2  Additional variables evaluated 
The following variables have been selected based on their well-known associations 
with increased cardio metabolic risk: 
• Variables associated with body composition: BMI, VAT, SAT, waist 
circumference, hip circumference, total fat mass, central and peripheral fat mass, 
fat free mass, and thigh subcutaneous fat 
• Variables associated with glucose homeostasis: 2-h glucose, fasting insulin, and 
insulin sensitivity as determined by using the clamp (GIR) and the HOMA-IR 
• Variables associated with lipoprotein profile: ApoB, LDL-C/ApoB, TG, LDL-C, 
and HDL-C 
• Variables associated with energy expenditure: TEE, REE, and PAEE 
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5.3.8 Statistical analysis 
The data are presented in the “Mean ± SD” format.  The normality of the variable 
distributions was assessed with a Kolmogorov-Smirnov test, and all variables were shown 
to be normally distributed. An independent Student t-test was used to compare the HEI-Ca 
between women with 2 or less components and women with 3 or more components of the 
MetS. The associations between HEI and physical or cardio-metabolic characteristics were 
examined by using bivariate Pearson correlation. The SPSS software (version 16) for 
Windows was used for the statistical analysis. The significance was accepted if p < 0.05 
held.  
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6 Results  
 
Physical and metabolic characteristic of the study population 
In this study, for the overall 88 obese and overweight postmenopausal women 
(subjects), the physical and cardio-metabolic characteristics are presented in Table 16 and 
Table 17, respectively. These subjects displayed wide variations in their body 
compositions, lipid profiles, and insulin sensitivities. As shown in Table 16, for this 
population the data “Mean ± SD” of the age and the BMI were obtained to be 58.2 ± 4.9 
years and 32.5 ± 4.9 kg/m2, respectively.  As shown in Table 17, 68.2% (n=60) of these 
women had total cholesterol greater than 5.2 mmol/L, and 31.8% (n=28) had LDL-C 
greater than 3.4 mmol/L. The mean and standard deviation (Mean ± SD) of the total HEI 
for this population was calculated to be 83.5 ± 9.  In addition, the data “Mean ± SD” for all 
components of HEI are shown in Table 18.  Table 19 illustrates the HEI cut-off point and 
the numbers of subjects in each category.  Seventy-seven subjects (87.5%) obtained the 
scores of  71.00, which corresponds to an excellent diet quality. Ten subjects (11.4%) 
obtained the scores between 62.00 and 70.00, which is defined as a good diet. Only 1 
subject (1.1%) obtained a score between 53.00 and 61.00, which represents a fair diet 
quality.  It is noticeable that no subject was found with a score of  52, which is the cut-off 
point for a poor diet quality.  
 
As shown in Table 20, according to NCEP ATPIII definition only sixteen subjects 
(18.4%) had  3 components of the MetS.  Among the seventy-one subjects (81.6%) who 
did not have the MetS, twenty-five subjects (35.2%) had two components, forty-three 
subjects (60.6%) presented one component, and three subjects had no component of the 
MetS. By design, the most common MetS component was obesity. Thus, eighty-two 
subjects (94.3%) of the population had waist circumferences more than 88 cm, while 
twenty-six (29.9%) of them displayed high TG ( 1.7 mmol/L). Furthermore, twenty 
subjects (23.0%) presented elevated HDL-C (<1.29 mmol/L), eight subjects (9.2%) had 
hypertension, and eight subjects (9.2%) had impaired fasting glucose. 
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Table 20 shows that the number of MetS components was not associated with the 
HEI score. As shown in Table 21, there was no significant difference in the HEI score 
between the subjects with number of factors  2 (without MetS) and the subjects with 
number of factors  3 (with MetS).  
 
Relationship between Healthy Eating Index (HEI) and physical and cardio-metabolic 
characteristics 
We examined the association between HEI and both physical and cardio-metabolic 
characteristics indices by using bivariate correlation.  As shown in Table 22, the HEI 
correlated negatively with the measure of body fat (total fat mass, abdominal fat mass, and 
central fat mass) and the measure of body weight, while VAT did not show any significant 
correlation with HEI. On the other hand, as indicated in Table 23, HEI had no significant 
relationship with fasting plasma glucose, 2-h glucose, insulin sensitivity (HOMA and 
clamp), blood pressure, and most markers of lipid metabolism (total cholesterol, LDL and 
HDL-C, ApoB, and TG).  It is noticeable that we found a significant positive association 
between HEI and LDL-C/ApoB. Furthermore, REE and TEE showed a significant negative 
correlation with HEI. 
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Table 16. Physical characteristics of overweight and obese postmenopausal women (n=88) 
Physical characteristics Mean S.D. Range 
Age (yrs) 58.2 4.9 46.0 – 68.7 
Weight (kg) 83.8 14.7 56.4 – 130.4 
BMI (kg/m2) 32.5 4.9 26.1 – 48.5 
Waist circumference (cm) (n=87) 103.6 11.9 81.5 – 153.0 
Hip circumference (cm) (n=87) 115.9 11.9 91.0 – 166.5 
Fat free mass (kg) 45.1 6.6 32.6 – 64.0 
Total fat mass (kg) 38.7 9.9 23.8 – 73.1 
Fat mass (%) 45.7 4.8 37.6 – 57.9 
Peripheral fat mass (kg) 19.0 4.9 11.5 – 34.9 
Central fat mass (kg) 18.7 5.5 11.1 – 39.0 
Abdominal fat mass (cm2) (n=86) 649.0 147.7 442.9 – 1025.9 
VAT (cm2) (n=87) 183.4 48.8 82.7 – 343.6 
SAT (cm2) (n=87) 465.4 121.3 301.7 – 776.0 
Thigh subcutaneous fat (cm2) 312.9 107.3 145.2 – 678.0 
S.D.: standard deviation, BMI: body mass index, VAT: visceral adipose tissue, SAT: subcutaneous adipose 
tissue 
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Table 17. Cardio-metabolic characteristics of overweight and obese postmenopausal 
women (n=88) 
Cardio-metabolic characteristics Mean S.D. Range 
Fasting glucose (mmol/L) 5.25 0.49 4.40 – 6.63 
2-h glucose (mmol/L) 6.40 1.87 3.59 – 11.03 
HOMA-IR (n=86) 3.53 1.56 1.11 – 9.50 
MMT3 (mg/min/kg FFM) (n=85) 11.12 3.19 4.71 – 22.87 
Total cholesterol (mmol/L) 5.49 0.76 3.27 – 6.94 
LDL-C (mmol/L) 3.22 0.67 1.43– 5.09 
HDL-C 1.47 0.34 0.98 – 2.66 
TG (mmol/L) 1.73 0.73 0.49 – 3.84 
ApoB (g/L) (n=87) 1.01 0.21 0.64 – 1.57 
LDL-C/ApoB (n=87) 3.23 0.64 1.51 – 5.81 
Systolic blood pressure (mmHg) 121 13 98 – 160 
Diastolic blood pressure (mmHg) 76 8 60 – 100 
TEE (kcal/day) 2525 404 1800 – 3572 
REE (kcal/day) 1318 195 930 – 1850 
PAEE (kcal/day) 954 288 381 – 1697 
Healthy Eating Index 83.51 9.24 56.13 – 99.22 
HOMA-IR: Homeostasis Model Assessment – Insulin Resistance, MMT3: Insulin sensitivity calculated by 
clamp, HDL: high density lipoprotein, LDL: low density lipoprotein, TG: triglycerides, TEE: total energy 
expenditure, REE: resting energy expenditure, PAEE: physical activity energy expenditure 
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Table 18. Healthy Eating Index (HEI) score and sub scores for overweight and obese 
postmenopausal women (n=88) 
HEI Components Mean  S.D. Range 
Grains 7.64 2.18 3.00-10.00 
Fruits and vegetables 18.05 3.31 8.80-20.00 
Milk products 7.16 2.81 0.00-10.00 
Meat and alternatives 9.43 1.44 2.50-10.00 
Total fat 7.81 2.51 0.00-10.00 
Saturated fat 7.53 3.19 0.00-10.00 
Cholesterol 8.37 3.20 0.00-10.00 
Sodium 8.03 2.46 0.00-10.00 
Dietary Variety 9.49 1.08 5.00-10.00 
Total HEI 83.51 9.24 56.13-99.22 
 
 
 
Table 19. Number of subjects according to HEI-Ca categories 
 
 
 
 
 
 
 
 
HEI categories Cut-off point for Total score Number of subjects  
Excellent 71 77 
Good 62-70 10 
Fair 53-61 1 
Poor  52 0 
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Table 20. Healthy Eating Index (HEI) score according to the number of metabolic 
syndrome components in overweight and obese postmenopausal (n=88) 
Data presented as mean ± standard deviation 
 
 
 
Number of metabolic 
syndrome components 
HEI score Number of subjects 
0 86.87 ± 2.76 3 
1 
84.68 ± 7.85 
43 
2 
80.23 ± 12.20 
25 
3 84.47 ± 7.81 14 
4 89.63 ± 0.18 2 
5 NS 0 
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Table 21. Comparison of the Healthy Eating Index (HEI) between women with and 
without metabolic syndrome 
 
  
 Without Metabolic 
syndrome 
 2 factors 
(n=71) 
With Metabolic 
syndrome 
 3 factors 
(n=16) 
p value 
 
HEI 83.21 ± 9.66 85.11 ± 7.48 0.461 
           Data presented as mean ± standard deviation 
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Table 22. Bivariate correlations of physical characteristics with Healthy Eating Index 
(HEI) (n=88) 
Physical characteristics Coefficient correlation p value 
Age 0.16 0.150 
Weight -0.28 0.010 
BMI -0.30 0.005 
Waist circumference (n=87) -0.24 0.023 
Hip circumference (n=87) -0.34 0.001 
Fat-free mass -0.22 0.043 
Total fat mass -0.26 0.013 
Fat mass (%) -0.16 0.130 
Peripheral fat mass -0.19 0.080 
Central fat mass -0.31 0.004 
Abdominal fat mass (n=86) -0.25 0.019 
VAT (n=87) -0.15 0.181 
SAT (n=87) -0.25 0.020 
Thigh subcutaneous fat -0.18 0.092 
           BMI: Body mass index, VAT: visceral adipose tissue, SAT: subcutaneous adipose tissue 
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Table 23. Bivariate correlations of cardio metabolic characteristics with Healthy Eating 
Index (HEI) (n=88)  
 
Cardio metabolic characteristics Coefficient correlation p value 
Fasting glucose 0.05 0.621 
2h-glucose 0.05 0.642 
HOMA-IR (n=86) -0.09 0.408 
MMT3 (n=85) 0.12 0.288 
Total cholesterol 0.12 0.259 
LDL-C 0.10 0.345 
HDL-C 0.17 0.121 
TG -0.10 0.378 
ApoB (n=87) -0.12 0.257 
LDL-C/ApoB (n=87) 0.25 0.019 
Systolic blood pressure -0.13 0.228 
Diastolic blood pressure -0.15 0.153 
TEE -0.22 0.040 
REE -0.24 0.025 
PAEE -0.12 0.282 
HOMA-IR: Homeostasis Model Assessment–Insulin Resistance,  
TG: triglycerides, TEE: total energy expenditure, REE: resting energy expenditure, PAEE: physical activity 
energy expenditure 
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7 Discussion 
 
We did not find any differences in diet quality between subjects with and without 
MetS. This may be, at least in part, due to the fact that few subjects had MetS (18.3%).  
The low prevalence of MetS might have hampered the statistical power which is necessary 
to detect significant relationship between MetS and diet quality. In addition, MetS is a 
heterogeneous syndrome with variable components.  As shown in Table 1, the definition of 
MetS chosen in our study is based on NCEP ATPIII [22]. According to this definition, an 
individual with three or more components including obesity, dyslipidemia, hypertension, 
and fasting plasma glucose  6.1 mmol/L is considered with MetS regardless of the 
components present.  Thus, the HEI may correlate with some, and not all, of the 
components. This may explain the lack of correlation between HEI (that we used in our 
study) and MetS. However, it should be noted that HEI is associated with some 
components of MetS such as waist circumference. 
 
We also examined the relationship between diet quality and individual components 
of MetS.  The main finding of our study was that diet quality correlated negatively with 
most measures of body fat including total fat, abdominal fat, and central fat mass. Similar 
results have also been observed in American Youth [16] and Framingham [225] studies.  
More research will be needed to determine which dietary components contribute to the 
cardio-metabolic risk, and whether the overall dietary pattern is important or not. 
 
Numerous studies have demonstrated the strong association between diet quality, 
specifically diets rich in saturated fat, and insulin resistance.  Surprisingly, we did not 
observe any correlation between HEI and fasting plasma glucose, 2-h glucose, insulin 
sensitivity (HOMA and clamp), and most markers of lipid metabolism (total cholesterol, 
LDL and HDL-C, ApoB, and TG).  One explanation may be that most subjects included in 
the study had an excellent diet score, while in other studies the HEI scores were notably 
lower (refer to Appendices 1 and 2). In general, the subjects who have an excellent diet 
quality consume less fat, and this may be one of the reasons why we do not see any 
association between markers of insulin sensitivity and diet quality.   
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The results of our study showed that most of our subjects had excellent HEI scores 
although they were overweight or obese. It has been shown that women generally have 
higher HEI diet quality scores, particularly in fruit and vegetable consumption, than men 
[18]. However, most of the subjects showed dyslipidemia in spite of their excellent diet 
quality. This observation suggests that diet quality alone is not sufficient to prevent 
metabolic alteration.  Since the main cause of obesity is high-calorie intake, it can be 
concluded that having a high-quality diet is not a sufficient condition for having a healthy 
metabolic profile, and that a high-calorie intake may contribute to obesity and potentially 
abnormal metabolic profile. Thus, it is probable that a person may need to restrict his/her 
calorie intake and have a high-quality diet simultaneously, in order to lose weight and 
improve his/her metabolic profile as a result. 
 
It should be noted that we found a significant positive association between HEI and 
the LDL-C/ApoB ratio. Since there is only one molecule of ApoB per LDL, the LDL-
C/ApoB ratio has been used so far in the literature to estimate the LDL size [126, 132, 
226].  Numerous studies have demonstrated that small dense LDL-C is more atherogenic 
and is associated with increased risk of CVD [127, 129].  Therefore, our results suggest 
that a higher diet quality is associated with a better lipid profile.  However, it should be 
noted that the LDL/ApoB ratio remains an indirect measure of the LDL size. Although in 
more than 90% of patients ApoB is associated with LDL, we observe in some patients with 
high TG and cholesterol that some ApoB’s bind to VLDL.  However, subjects with high 
cholesterol and/or TG were excluded from our study.  Further studies should be done to 
examine the relationship between diet quality and direct measure of LDL size. 
 
One limitation of our study is that subjects with diabetes, hypertriglyceridemia, 
hypertension, and cardiovascular diseases were excluded, while all women were either 
overweight or obese. Thus, the study population was relatively healthy, that led to a small 
number of women with MetS.  This situation had probably limited our ability to detect the 
interaction between diet quality and MetS. Further studies should be done to include a 
larger number of women with MetS as compared to our study population. 
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Another limitation of our study is due to the use of dietary journal.  For example, 
although subjects had been taught by dieticians to estimate the portion sizes of the foods 
they consumed, the possibility remained that the subjects made mistakes in estimating their 
portion sizes. In addition, it was possible that the subjects did not report all foods that they 
consumed. For example, consumption of multivitamins, omega-3 pills, and some 
supplements for lowering cholesterol and TGs might had been forgotten by some subjects.  
All these issues could alter the results of this study. 
 
Despite these limitations, our results were strengthened by using the gold standard 
techniques for the evaluation of various metabolic risk factors in a relatively well-
phenotype cohort. 
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8 Conclusion and Future Work 
 
Our results demonstrated that HEI is associated with fat distribution, as well as 
LDL size, in a cohort of overweight and obese postmenopausal women.   
 
Further statiscal analyses could be performed by using the components of MetS as 
dependent variables and using HEI as the independent variable to examine the relationship 
between the MetS and diet quality.  
 
Most of the women included in our study presented a relatively healthy profile as 
shown by the small number of subjects with the MetS. Thus, our future work may include 
the individuals with complications in order to investigate the association between diet 
quality and the MetS. It would also be useful to include more subjects in our future study 
in order to increase the power to do statistical analysis. 
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APPENDICES 
  
Appendix 1. Canadian Food Guide, 1997 
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Appendix 1. Continued 
 
 
Note: In our study, one serving of alcohol is equal to (a) 1.5 onces of distilled alcohol (e.g. Vodka, 
Jin, and Whiskey), (b) 4 onces of sec wine, (c) 2 onces of sec Sherry, or (d) 12 onces of beer. 
 
 
xxii 
 
 
 
 
Appendix 2. Tables for mean comparison of HEI 
 
 
Table A-I. Scores of Healthy Eating Index Components (n=7643)* [15] 
*weighted data for persons aged 2 years and older and 3 day dietary intake data.  
** included egg, nuts and some legumes 
 
 
 
 
HEI component Mean % observation at 
score 0 
% of observation 
at score 10 
Grain 6.2 < 0.5 11.1 
Vegetables 6.1 0.8 17.1 
Fruits 4.0 13.2 13.6 
Milk 6.7 0.2 32.5 
Meat** 7.5 < 0.5 32.2 
Total fat 6.3 5.0 20.3 
Saturated fat 5.1 18.7 19.5 
Cholesterol  8.0 10.8 69.1 
Sodium 7.0 9.6 36.2 
variety 7.0 2.8 32.9 
Total Score 63.9   
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Table A-II. Diet Quality of Montreal-Area Adults Needs Improvement: Estimates from a 
Self-Administered Food Frequency Questionnaire Furnishing a Dietary Indicator Score 
[18] 
 
HEI 
components 
Highest 
possible score 
Male(n=105) Female(n=143) All(n=248) 
Grain 10 5.1±2.5 5.4±2.5 5.3±2.5 
Vegetable and 
fruit 
20 11.0±5.3 14.0±5.2**** 12.7±5.4 
Milk 10 7.5±2.8 7.5±2.9 7.5±2.9 
Meat and 
alternatives 
10 9.2±1.5 8.9±1.9 9.0±1.7 
%total fat 10 7.3±2.8* 6.5±3.2 6.9±3.1 
% saturated 
fat 
10 6.1±3.7 5.9±3.8 6.0±3.8 
Cholesterol  10 7.3±3.9 8.8±2.8*** 8.2±3.3 
Sodium  10 7.3±3.4 8.6±2.5** 8.1±3.0 
Dietary variety 10 9.4±1.1 9.3±1.3 9.3±1.2 
Total score 100 70.3±10.5 74.9±10.9*** 73.0±11.0 
 
* P<0.05 
** P<0.01 
*** P<0.001 
**** P<0.0001 
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Table A-III. Healthy Eating Index Scores Are Associated With Blood Nutrient 
Concentrations in the Third National Health and Nutrition Examination Survey [209] 
 
HEI components 
CSFII 
1989 
n=3997 
CSFII 
1996 
N=4800 
NHANESIII 
1989-94 
N=26,348 
NHANES 
1999-2000 
N=8070 
Grains 6.1 6.7 6.7 6.7 
Vegetables 5.9 6.3 5.7 6.0 
Fruits 3.7 3.8 3.8 3.8 
Milk 6.2 5.4 6.6 5.9 
Meat 7.1 6.4 6.8 6.6 
Total fat 6.3 6.9 6.5 6.9 
Saturated fat 5.4 6.4 6.1 6.5 
Cholesterol 7.5 7.9 7.8 7.7 
Sodium  6.7 6.3 6.0 6.0 
Dietary variety 6.6 7.6 7.7 7.7 
Total Score 61.4 63.8 63.8 63.8 
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Table A-IV. Validation of Healthy Eating Index with Use of Plasma biomarkers in a 
clinical sample of women [208]  
 
*includes eggs,nuts and legumes 
** to obtain value, criterion was multiplied by 10 (ie, for good score, score>80) 
 
 
 
 
 Percentage obtaining score 
HEI Component Mean 
Poor 
Score < 5 
Needs 
Improvement 
Score 5 - 8 
Good 
Score > 8 
Grain 7.2 18.5 40.9 40.6 
Vegetables 8.4 10.0 24.1 65.9 
Fruits 7.2 27.1 17.1 55.9 
Milk 5.9 42.4 27.1 30.6 
Meat * 8.9 6.5 17.1 76.5 
Total fat 8.3 12.6 18.8 68.5 
Saturated  fat  8.1 17.1 12.1 70.9 
Cholesterol  9.3 5.6 4.4 90.0 
Sodium  8.0 13.8 22.9 63.2 
Dietary Variety  5.9 37.4 38.5 24.1 
Total Score ** 77.3 1.8 49.4 48.8 
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Table A-V. Predictors of Diet Quality among Overweight and Obese postmenopausal 
women [227]  
 
Characteristics N 
DQI score 
Mean ± SD 
HEI score 
Mean ± SD 
Age group: 
50-55 
56-65 
66-75 
P-value 
   
43 7.8 ± 2.9 61.8 ± 13.6 
76 8.3 ± 3.0 63.8 ± 11.8 
45 8.0 ± 2.7 63.4 ± 11.6 
 0.63 0.70 
BMI 
24-28 
28-31 
>31 
P-value 
   
50 7.0 ± 2.9 65.7 ± 12.4 
54 8.2 ± 2.6 63.2 ± 11.8 
60 8.9 ± 2.9 61.0 ± 12.2 
 0.003 0.13 
% body fat 
34.1-45.0 
45.1-49 
>49 
P-value 
   
50 7.3 ± 2.8 64.7 ± 13.1 
56 7.9 ± 2.9 63.3 ± 12.3 
58 8.8 ± 2.8 61.7 ± 11.2 
 0.02 0.44 
Educational level 
High school or less 
College 
PostBS. or advance 
degree 
P-value 
   
18 9.5 ± 3.7 56.2 ± 11.7 
82 8.2 ± 2.7 63.1 ± 12.0 
64 7.5 ± 2.5 65.1 ± 12.0 
 0.02 0.02 
Smoking history: 
Never 
Former 
P-value 
   
86 8.5 ± 2.6 62.8 ± 12.5 
78 7.6 ± 3.1 63.6 ± 11.8 
 0.05 0.67 
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Table A-VI. Adherence to the Dietary Guidelines for Americans and risk of major chronic 
disease in women [210] 
HEI 
Components 
CSFII 
1996* 
HEI score 
NHS1984 
HEI-F 
score 
Criteria for max score 10 
Women19-50         Women  51 
 
Grains 6.7 4.9±2.2 9.1 7.4 0 
Vegetables 6.3 8.7±1.9 4.2 3.5 0 
Fruit 3.8 7.2±2.9 3.2 2.5 0 
Milk 5.4 6.1±2.9 2.0 2.0 0 
Meat 6.4 8.3±2.0 2.4 2.2 0 
Total fat 6.9 6.5±3.0  30  45 
Saturated fat  6.4 5.2±3.5 < 10  15 
Cholesterol  7.9 7.4±3.6 < 300  450 
Sodium 6.3 5.0±3.2 < 2400  4800 
Dietary Variety 7.6 5.0±3.1 16  6 
Total Score 64 64.4±12.5   
*CSFII subset (n=428) was a subsample of women aged 37-66, with  12 yr of schooling.  
Pregnant and lactating women are excluded. 
HEI scoring was adopted from Kennedy et al. [15] 
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Appendix 3. Consent form of the Weight-Loss Weight-Regain (WLWR) study 
 
FORMULAIRE DE CONSENTEMENT 
 
Titre du projet de recherche : FACTEURS MÉTABOLIQUES ET GÉNÉTIQUES 
PRÉDISANT LE REGAIN DE POIDS CHEZ LES FEMMES POST-
MÉNOPAUSÉES ET OBÈSES 
 
Investigateurs principaux : Dominic Garrel, MD. Ph.D., Martin Brochu, Ph.D., Rémi 
Rabasa-Lhoret MD. Ph.D., et collaborateurs du Département de nutrition et de 
kinésiologie de la faculté de médecine de l’Université de Montréal. 
 
1. OBJECTIFS 
Déterminer si un déséquilibre énergétique étant relié à une dépense énergétique trop 
faible ou à un apport énergétique trop élevé ou à une combinaison des deux, et la 
sensibilité à l’insuline contribuent à l’obésité chez les femmes.  Un deuxième objectif 
sera de déterminer si la présence ou l’absence du gène de l’obésité influence la 
capacité à perdre du poids et à maintenir cette perte.  Un troisième objectif sera de 
vérifier si l’entraînement musculaire associé à la consultation nutritionnelle peut 
maintenir l’amélioration du maintien et/ou de la perte de poids chez ce groupe de 
femmes.  Un quatrième objectif sera de mesurer les niveaux de certaines hormones 
sécrétées par les tissus adipeux, le tractus gastro-intestinal, l’hypothalamus et 
l’hypophyse (ghrelin, acylation stimulating protein (ASP), leptin, adiponectin, resistin,  
NPY, orexin A et B, IGF-I et GH). 
 
2. HISTORIQUE 
L’obésité est un désordre chronique qui affecte entre autres les femmes plus âgées.  
Jusqu’à présent, il n’est pas clair si l’apport alimentaire excessif et/ou un faible taux de 
dépense énergétique contribuent au taux élevé d’obésité chez les femmes plus âgées. 
Certains facteurs hormonaux dérivés du tractus gastro-intestinal ainsi que des tissus 
adipeux semblent également jouer un rôle prépondérant quant au contrôle de l’appétit 
et à la dépense énergétique au quotidien. Une mutation génétique a récemment été 
découverte qui pourrait jouer un rôle important dans l’accumulation excessive de gras.  
Nous sommes intéressés à déterminer si les individus possédant cette mutation 
démontrent un taux de dépense énergétique plus bas, un niveau hormonal différent, 
une sensibilité plus faible à l’insuline, une capacité de dégradation et d’utilisation des 
graisses moins efficace comparées aux individus ne possédant pas la mutation.  Nous 
aimerions démontrer que l’entraînement musculaire aura un effet sur l’augmentation 
de la masse maigre, du métabolisme basal, de la force musculaire ce qui représente une 
adaptation métabolique directe et indirecte qui pourrait maintenir la perte de poids et 
éviter le regain de poids.  . 
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3. NATURE DU PROTOCOLE 
L’étude est divisée en six parties : 
A. Recrutement 
B. Stabilisation du poids corporel (4 semaines 
C. Restriction calorique (26 semaines)  
D. Stabilisation du poids corporel (4 semaines)  
E. Suivi (52 semaines) 
F. Stabilisation du poids corporel (4 semaines)  
 
A.Recrutement 
Lors de la période de recrutement, vous serez soumis à certains examens  pour 
déterminer si vous êtes en mesure de participer à l’étude (voir critères d’exclusion et 
description des tests).  Une fois ces tests complétés, vous pourrez débuter l’étape 
suivante si votre profil correspond à celui requis pour l’étude. 
 
B.Stabilisation du poids corporel (4 semaines) et série de tests 
Cette période consiste à maintenir votre poids le plus stable possible avant les tests qui 
serviront à déterminer votre condition physique.  Elle est nécessaire pour s’assurer que 
les tests sont représentatifs d’un état stable et que vous n’êtes pas encore en phase de 
changement.  Ensuite, vous subirez une batterie de tests décrits plus loin nécessitant 7 
visites au laboratoire, et une visite en milieu hospitalier.  Avant de passer à l’étape 
suivante, vous serez assigné au hasard, soit au groupe avec exercice ou sans exercice. 
 
C.Restriction calorique (26 semaines) 
Il s’agit de la partie de l’intervention dont l’objectif principal est de vous faire perdre 
du poids, soit environ 10 % de votre masse grasse initiale.  Votre alimentation sera 
contrôlée et la quantité d’énergie que vous allez consommer par jour sera limitée en 
fonction de votre métabolisme qui aura été évalué.  Il s’en suivra une restriction 
énergétique d’environ 500 à 800 kcals par jour.  Vous serez accompagnée par une 
nutritionniste pour tout ce qui concerne votre alimentation, en suivi individuel et en 
groupe. 
 
D.Stabilisation du poids corporel (4 semaines) et série de tests 
Le groupe exercice termine l’étude.  Le groupe sans exercice sera divisé en 2 groupes : 
avec exercice et sans exercice. 
 
E.Suivi (52 semaines) 
 
Lors de la phase de suivi, vous devrez compléter une fois par mois un rappel 
alimentaire de trois jours ainsi que porter un petit appareil (TriTrac) de la dimension 
d’un téléavertisseur, qui mesurera votre niveau d’activité pendant la journée. Vous 
serez également pesée, et vous pourrez, au besoin, rencontrer la nutritionniste pour 
toutes questions lors de cette rencontre.  Les professionnels de l’équipe de recherche 
demeurent à votre entière disposition pendant cette période.   
 
F.Dernière stabilisation du poids corporel (4 semaines) et série de tests. 
Les tableaux 1.1 et 1.2 et 1.3 résument la chronologie des évènements. 
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Tableau 1.1   L’APROCHE EXPÉRIMENTALE 
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Veuillez prendre note que cette expérience demandera un dévouement en temps 
important de la part de tous les volontaires. 
 
4. CRITÈRES D’EXCLUSION 
- Souffrir de : 
o claustrophobie 
o  diabète ou d’une mauvaise tolérance au glucose (glucose plasmatique à 
jeun > 125 mg/dL) 
o maladie thyroïdienne non traitée 
o maladie hépatique ou rénale (foie ou rein) 
o anorexie nerveuse 
o asthme nécessitant un traitement oral aux stéroïdes 
o hyperlipidémie (cholestérol < 6 nM/L; triglycérides >2 nM/L) 
o maladies cardiovasculaires ou maladies vasculaires périphériques 
- Suivre présentement ou au courant des trois derniers mois : 
o un traitement à l’œstrogène 
o une thérapie de remplacement d’hormone 
o un traitement aux narcoleptique 
o un traitement chronique aux stéroïdes 
o un traitement avec des agents atténuant les lipides 
- Avoir des antécédents d’abus de drogues ou d’alcool 
- Avoir des valeurs de laboratoire anormales (hématocrites <32 ou >48, glucose 
à jeun >7,4 nM/L, créatine >2.0) 
- Utilisation de médicament ou drogues pour la perte de poids, de médicaments 
ou drogues psychoactifs, et des agonistes adrénergiques peu importe la voie 
- Être fumeur 
 
 
5. DESCRIPTION DES TESTS POUR LE DÉPISTAGE 
 
PRISE DE SANG ET DÉPISTAGE DU GÈNE DE L’OBÉSITÉ 
Un petit échantillon de sang (environ  ½ cuillerée à thé) sera prélevé pour 
premièrement mesurer le profil lipidique complet (cholestérol, triglycérides) de votre 
sang, et deuxièmement pour effectuer un test de dépistage du gène d’obésité.  Ce test 
ne sera effectué qu’une seule fois au début de l’étude. 
BÉNÉFICES 
Vous serez informé si vous avez des valeurs de lipides dans la sang trop élevés ainsi 
que si vous êtes porteur du gène susceptible de causer l’obésité 
RISQUES ET INCONVÉNIENTS 
Des ecchymoses ou une décoloration de la zone de prélèvement sanguin sont les seuls 
inconvénients reliés à ce test 
 
TEST DE TOLÉRANCE AU GLUCOSE 
Ce test est utilisé pour diagnostiquer le diabète.  Un petit échantillon de sang sera 
prélevé (½ cuillerée à thé).  Par la suite, on vous demandera de boire une boisson 
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sucrée (glucose) à saveur d’orange.  À chaque demi heure pendant deux heures, un 
petit échantillon de sang sera prélevé pour un total de 3 cuillerées à thé. 
BÉNÉFICES 
Vous serez informé de votre niveau de tolérance au glucose en relation avec le diabète. 
RISQUES ET INCONVÉNIENTS 
Les seuls risques impliqués lors de ce test inclus des ecchymoses ou une décoloration 
de la zone de prélèvement sanguin. 
 
EXAMEN PHYSIQUE  
L’examen physique ainsi que l’historique médical et d’obésité seront effectués par le 
médecin participant dans cette étude, lors de votre première visite à l’unité 
métabolique.  Aucun risque et inconvénient ne sont associés à cet examen. 
BÉNÉFICES 
Vous serez informé de votre état de santé en détail. 
 
ELECTROCARDIOGRAMME (ECG 
L’électrocardiogramme va mesurer l’activité de votre cœur et nous serons en mesure 
de détecter toutes anomalies de votre coeur.  Des électrodes seront installées à 
différents points sur votre thorax, et des mesures seront enregistrées.  Un médecin sera 
présent durant le test.   
BÉNÉFICES 
Vous obtiendrez une évaluation précise de votre activité cardiaque. 
RISQUES ET INCONVÉNIENTS 
Peu de risques sont associé à cet examen.  Un médecin sera présent durant le test et 
l’équipement médical nécessaire aux urgences cardiaques sera disponible.  Le 
personnel de recherche est certifié en réanimation cardio-respiratoire. 
 
 
 
6. DESCRIPTION DES TESTS DE MESURE 
 
TEST DE TOLÉRANCE AU GLUCOSE 
Ce test est utilisé pour diagnostiquer le diabète.  Un petit échantillon de sang sera 
prélevé (½ cuillerées à thé).  Par la suite, on vous demandera de boire une boisson 
sucrée (glucose) à saveur d’orange.  À chaque demi heure pendant deux heures, un 
petit échantillon de sang sera prélevé pour un total de 3 cuillerées à thé. 
BÉNÉFICES 
Vous serez informé de votre niveau de tolérance au glucose en relation avec le diabète. 
RISQUES ET INCONVÉNIENTS 
Les seuls risques impliqués lors de ce test inclus des ecchymoses ou une décoloration 
de la zone de prélèvement sanguin. 
 
DÉPISTAGE DES NIVEAUX D’HORMONES SÉCRÉTÉES PAR LES TISSUS 
ADIPEUX, LE TRACTUS GASTRO-INTESTINAL, L’HYPOTHALAMUS ET 
L’HYPOPHYSE 
 
Les hormones du tissu adipeux, du tractus gastro-intestinal de l’hypothalamus et de 
l’hypophyse sécrètent des hormones (ghrelin, acylation stimulating protein, leptin, 
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adiponectin, resistin, NPY, orexin, IGF-I et GH) seront dosées à partir de l’échantillon 
de sang prélevé à la visite 1. Le dosage est effectué par radioimmunoessai (RIA), une 
méthode éprouvée pour la quantification des niveaux d’hormones plasmatiques. 
BÉNÉFICES 
Si vous le désirez vous serez informé des niveaux d’hormones susceptibles 
d’influencer la santé métabolique. 
RISQUES ET INCONVÉNIENTS 
Aucun associé à cette procédure. 
 
MESURE DE LA CAPACITÉ AÉROBIE  (V0²max) 
Le V0²max sert à mesurer l’habileté de votre corps à consommer de l’oxygène pendant 
un exercice.  Lorsque combiné avec un moniteur de fréquences cardiaques, nous 
pouvons également utiliser ce test comme un indicateur de votre forme 
cardiovasculaire.  Ce test sera exécuté sur un ergo cycle (vélo stationnaire) maintenu à 
une vitesse constante.  Le niveau de difficulté de l’exercice sera augmenté à chaque 
deux minutes.  Le test sera arrêté lorsque vous serez fatigué.  Votre consommation 
d’oxygène sera mesurée à chaque palier d’effort en mesurant votre souffle dans un 
appareil buccal en caoutchouc.  Votre tension artérielle sera également mesurée.  Ce 
test prendra environ une heure à compléter (approximativement 10-15 minutes 
d’exercice). 
BÉNÉFICES 
Vous obtiendrez une évaluation précise de votre capacité aérobie à l’aide d’une mesure 
directe.  La capacité aérobie est un des déterminants important de la santé. 
RISQUES ET INCONVÉNIENTS 
Les risques associés à ce test sont; essoufflement, souffle court, fatigue, inconfort 
musculaire local.  Un rythme cardiaque irrégulier ou même des complications 
cardiaques peuvent survenir lors d’efforts intenses. 
Comme mesure préventive, vous serez suivi à l’aide d’un électrocardiogramme pour 
mesurer l’activité de votre cœur et le test sera arrêté si des anomalies se produisent.  
Un médecin sera présent durant le test et l’équipement médical nécessaire aux 
urgences cardiaques sera disponible.  Le personnel de recherche est certifié en 
réanimation cardio-respiratoire.  Malgré l’intensité associée à ce test, les risques de 
troubles cardiaques sont improbables.  Les arrêts cardiaques sont extrêmement rares  
(< 1 décès en 10000 tests) chez les individus sans antécédents de maladies cardiaques. 
 
MESURES ANTHROPOMÉTRIQUES 
Il s’agit de mesures des dimensions de votre corps.  Des circonférences, largeurs et 
longueurs seront mesurées ainsi que des plis cutanés dans le but de déterminer votre 
composition corporelle.  Ces mesures seront ensuite comparées avec les valeurs 
obtenues sur le DXA. 
BÉNÉFICES 
Vous aurez une estimation de votre composition corporelle avec des mesures 
accessibles et pouvant être reproduites de façon peu dispendieuse. 
RISQUES 
Il n’y a pas de risque associé à ces mesures.  Les seuls inconvénients sont les marques 
au crayon (lavable à l’eau) pour identifier les repaires anatomiques. 
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MÉTABOLISME DE REPOS  
Même au repos, votre corps dépense de l’énergie (calorie).  Ce test nous permet de 
mesurer la quantité de calorie que vous brûlez au repos.  Cette mesure est effectuée de 
bonne heure le matin.  Lorsque vous arriverez, vous vous coucherez dans un lit et un 
capuchon en plexiglas, alimenté en air frais, sera placé sur votre tête.  L’air expiré sera 
analysé par échantillons et les pourcentages d’oxygène et de dioxyde de carbone seront 
déterminés.  En mesurant le rythme d’expiration, nous déterminerons la quantité 
d’oxygène que vous consommez et l’appareil calculera le nombre de calories 
dépensées.  Ce test nécessite votre présence en position allongée et calme dans un lit 
pour approximativement 40 minutes. 
BÉNÉFICES 
Vous obtiendrez une mesure précise de votre dépense énergétique au repos. 
RISQUES ET INCONVÉNIENTS 
Il n’y a aucun risque associé à ce procédé.  Les seuls inconvénients sont associés aux 
personnes souffrant de claustrophobie, le capuchon étant un espace restreint, ainsi que 
l’importance de demeurer totalement inactif pendant toute la durée des mesures soit 40 
minutes.  
 
COMPOSITION CORPORELLE ET TOMOGRAPHIE   (DXA) 
Ce test déterminera la quantité de muscle et de graisse dans votre corps.  Votre poids et 
grandeur seront mesurés.  Ensuite, nous utiliserons une méthode nommée « dual 
photon x-ray » densitométrie (DXA) pour mesurer votre densité osseuse, pourcentage 
de graisse et de masse maigre.  Vous devrez demeurer couché sur la table d’examen, 
habillé normalement, alors qu’un rayon x à faible densité balayera votre corps pendant 
10 minutes. 
 
TOMOGRAPHIE 
La tomographie permet de déterminer combien de graisse se situe au niveau de 
l’abdomen et des cuisses.  Pendant ce test, vous serez également allongé mais avec les 
bras étendus vers le haut au-dessus de la tête.  Des mesures de deux secondes sur une 
surface de 5mm seront effectuées au niveau de l’abdomen, du nombril ainsi qu’à mi-
cuisse par un appareil à rayon X.  Le tout prend environ 15 minutes. 
BÉNÉFICES 
Vous obtiendrez une mesure précise de votre composition corporelle déterminée à 
l’aide de matériel de haute technologie ainsi qu’une évaluation non médicale de votre 
densité osseuse.  La composition corporelle est un autre déterminant important de 
votre santé. 
RISQUES ET INCONVÉNIENTS 
Le seul risque se situe au niveau de l’exposition aux rayon X qui se chiffre à 0.03 
millirem pour le DEXA, ce qui est moins que l’exposition ambiante naturelle pour une 
journée, et de 1.12 Rem pour la tomographie qui représente moins que le dosage 
maximum permis de 5 Rem par année.  Veuillez considérer que cette exposition aux 
radiations est nécessaire pour les objectifs de l’étude et n’est pas requise pour des soins 
médicaux. 
 
QUESTIONNAIRES 
Vous devrez également répondre à des questionnaires alimentaires, psychologiques et 
sociodémographiques le tout prenant environ une à deux heures.  Ces tests sont 
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réalisés avec papier et crayon ou lors d’un entretien.  Les questions posées chercheront 
à évaluer ; votre consommation d’aliments, des qualités tels que la mémoire, 
l’appréciation de la vie, la satisfaction, la dépression ainsi que votre humeur. 
 
« CLAMP » HYPERINSULINÉMIQUE-EUGLYCÉMIQUE 
À votre arrivé nous prendrons votre poids et votre taille, vous irez à la toilette, puis  
vous serez installé dans un lit et un cathéter intraveineux (tube de plastique) sera placé 
dans une veine de votre bras.  Un second cathéter, pour les prélèvements sanguins, sera 
placé dans une veine du dos de votre main qui elle, sera ensuite placée dans une boite 
chauffante pour la garder au chaud.  On vous demandera par la suite de ne pas 
consommer de la nourriture ni aucune boisson quelconque autre que de l’eau jusqu’à la 
fin du test.  Une demi-heure plus tard, nous commencerons à vous donner un liquide 
par l’intermédiaire du cathéter dans votre bras.  Ce liquide est constitué de sucre 
marqué avec un isotope stable non radioactif.  L’infusion du sucre marqué se 
poursuivra durant toute la durée du test.  Une heure plus tard, nous débuterons 
l’infusion d’insuline.  L’insuline est une hormone naturelle produite par votre 
organisme.  Son action principale consiste à diminuer le niveau sanguin de sucre.  Pour 
éviter une diminution du sucre, nous vous procurerons une quantité de sucre dissoute 
dans l’eau par l’intermédiaire du cathéter.  Cette solution (sucre + eau) est utilisée 
couramment dans les hôpitaux lorsque l’alimentation est fournie par les veines.  Pour 
les trois heures suivantes, de petits échantillons de sang (approximativement ½ 
cuillerées à thé) seront prélevés à chaque 5 minutes pour mesurer votre niveau sanguin 
de sucre afin de pouvoir ajuster la quantité de sucre administrée.  Un total de 12 
cuillerées à thé sera prélevé.  Pendant la durée du test, vous pourrez visionner un film 
de votre choix.  Après le test, un repas vous sera servi. 
BÉNÉFICES 
Ce test nous aidera à déterminer votre prédisposition au diabète ainsi que votre 
capacité à utiliser le sucre. 
RISQUES ET INCONVÉNIENTS 
Un isotope stable comme celui utilisé dans cette technique n’est PAS RADIOACTIF 
et ne présente aucun danger.  Les prises de sang et l’infusion de liquide requièrent 
l’installation d’un tube dans une veine.  Quelques inconforts mineurs peuvent être 
anticipés pendant la pose des tubes.  Des ecchymoses, de l’inflammation et le blocage 
de la veine (thrombose) peuvent survenir lorsque les tubes sont installés.  Il existe un 
faible risque d’infection.  Le risque le plus important associé à l’infusion d’insuline 
(« clamp ») est l’hypoglycémie (taux de sucre bas).  Un faible taux de sucre dans le 
sang peut générer de l’anxiété, augmenter votre rythme cardiaque et vous faire 
transpirer.  Les conséquences potentielles sérieuses de l’hypoglycémie sont la perte de 
connaissance et convulsions.  Un professionnel entraîné pour faire face à ces situations 
supervisera le test et les mesures fréquentes de votre taux de sucre minimiseront ces 
risques. 
 
EAU DOUBLEMENT MARQUÉE 
La méthode de l’eau doublement marquée est une technique relativement nouvelle 
pour estimer le nombre total de calories dépensées sur une base journalière (votre 
dépense énergétique journalière), et ce pendant 10 jours.  Cette technique nous permet 
d’examiner votre dépense énergétique avant et après le programme de perte de poids.  
Par conséquent, cette technique sera utilisée trois fois pendant l’étude.  Nous vous 
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demanderons de prendre un verre d’eau « lourde », qui aura été marquée par deux 
substances naturelles, le deutérium (²Hydrogène) et le 18oxygène.  Ces substances ne 
sont pas radioactives.  En mesurant le rythme d’élimination de ces substances dans des 
échantillons d’urine périodiques, il nous est possible de mesurer la dépense 
énergétique totale. 
BÉNÉFICES 
Vous serez informé du nombre précis de calories que vous utilisez pour effectuer vos 
tâches pendant une journée déterminée. 
RISQUES ET INCONVÉNIENTS 
Il n’y pas de danger associé à la consommation de cette eau. 
 
ACCÉLÉROMÈTRE « RT3 TRI-AXIAL » :  
Le « RT3 Tri-axial » est un accéléromètre de la taille d’un téléavertisseur que vous 
porterez à votre taille pendant trois jours, sur une base mensuelle, et ce pour la période 
de perte de poids et les 52 semaines d’observation. Cet appareil mesure les 
mouvements que vous effectuer dans les trois dimensions. Il permet de déterminer la 
quantité d’énergie (kcal) dépensée par vos mouvements sur la durée d’utilisation de 
l’appareil, soit 5 jours dans le cas de cette étude.  
BÉNÉFICE : les résultats du « RT3 Tri-axial » vous permet de connaître la quantité 
d’énergie que vous dépenser selon votre activité journalière. 
RISQUES ET INCONVÉNIENTS : aucun inconvénient n’est relatif au « RT3 Tri-
axial ». Bien qu’il ne soit pas lourd (70 grammes avec batterie), il peut être 
incommodant de le porter avec soi à tout moment pour une période donnée. Il ne peut 
toutefois pas causer de douleur et ne peut être utilisé dans l’eau. 
 
 INTERVENTION NUTRITIONNELLE 
On vous informera comment stabiliser votre alimentation ainsi que votre poids pour 
une période d’un mois avant les tests en laboratoire.  Durant la période de perte de 
poids, un programme vous sera enseigné adapté à vos habitudes alimentaires.  Une 
nutritionniste certifiée dispensera des cours sur des habitudes alimentaires saines lors 
de classes (pour approximativement 1 ½ heure par séance) qui seront tenue tout au 
long de la période de six mois associée au programme de perte de poids.  Ces cours 
sont facultatifs. 
 
RISQUES ET INCONVÉNIENTS 
Vous serez supervisé par le personnel médical pendant toute la durée du protocole de 
recherche.  Les tests vous seront expliqués en détails par le personnel en place avant  
aspect de l’étude.   Le programme de perte de poids sera supervisé par un médecin, les 
classes seront dispensées par une nutritionniste certifiée, et les risques associés au 
programme de perte de poids sont minimes.  Néanmoins, une incidence accrue de 
calculs vésiculaires lors de perte de poids rapide est présente.  Cependant, ce 
phénomène se retrouve surtout en présence de régimes à très faible teneur en calories 
(<800 kcal/jour) ce qui n’est pas le cas dans notre programme.  Il y a des chances de 
changement d’humeur pendant la perte de poids.  Des études ont démontré autant des 
changements positifs (impression de bien-être) que négatifs (dépression et diminution 
de l’estime de soi) pendant des périodes de perte de poids. 
 
BÉNÉFICES 
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La participation à cette étude vous offre la possibilité de subir un examen physique, 
d’obtenir de l’information sur votre tension artérielle et votre niveau de cholestérol, de 
passer un test aérobie maximal, ainsi que de recevoir des informations nutritionnelles 
et médicales reliées à l’étude.  Vous aurez également l’opportunité de participer à un 
programme de perte de poids, ainsi qu’un programme d’entraînement superviser par 
des médecins, nutritionniste, entraîneur et kinésiologues spécialisés dans la perte et le 
maintien du poids. 
 
EXERCICE / ENTRAÎNEMENT MUSCULAIRE 
 
Vous serez assignée aléatoirement (au hasard) à l'un des deux groupes expérimentaux; 
soit "restriction calorique seul" ou "restriction calorique + entraînement musculaire en 
force". Les participantes qui auront été sélectionnées pour participer au groupe 
"entraînement musculaire en force" s'entraîneront 3 jours non consécutifs par semaine 
dans une salle de musculation (ex: lundi, mercredi et vendredi) sous la supervision 
d'un spécialiste en conditionnement physique, tel que décrit antérieurement (Poehlman 
et al. 2000).  
L'intensité de l'entraînement sera entre 70% et 80%, soit environ 10 répétitions par 
exercice. Chaque séance d'entraînement comprendra une période d'échauffement 
d'intensité légère sur bicyclette (5 minutes), suivie par une période d'étirements 
statiques de 10 minutes ciblant les principaux groupes musculaires qui seront 
mobilisés pendant la séance d'entraînement. Toutes les séances d'entraînement seront 
comptabilisées afin de suivre votre progression et pour réajuster la prescription 
d'exercice au besoin. 
Les charges d'entraînement seront établies et réajustées au besoin pour que le nombre 
de répétitions de chacune des trois séries de chaque exercice ne dépasse pas 10. Une 
période de repos de 60 à 90 secondes sera accordée entre chaque série. Selon notre 
expérience avec ce type de programme d'exercice, nous devrions avoir un taux 
d'abandon d'approximativement 15% à 20% à la fin de l'étude (Poehlman et al. 2000). 
Les charges seront par la suite progressivement augmentées lors des semaines 2 et 3 
afin d'atteindre 70% à 80% du 1-RM (charge maximale déplacée une seule fois), et ce 
pour le reste de l'étude. Cette stratégie est utilisée afin de permettre une meilleure 
adaptation des participantes à l'entraînement et afin d'éviter les blessures pouvant être 
causées par un entraînement trop intensif en phase d'initiation. 
BÉNÉFICES 
L’entraînement en musculation permet d’augmenter la force et la masse musculaire en 
plus d’améliorer la capacité fonctionnelle des participants. 
RISQUES ET INCONVÉNIENTS 
Certaines douleurs musculaires et articulaires peuvent survenir suite à un entraînement 
en musculation.  Cependant, ces douleurs sont passagères et les périodes de repos 
prévues sont suffisantes pour assurer une récupération adéquate.  Des blessures 
musculaires et articulaires plus importantes peuvent également survenir suite à une 
mauvaise utilisation des équipements.  Cependant, sous la supervision de personnel 
compétent ces risques sont considérablement réduits. 
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7. PERSONNES RESSOURCES 
 
Dominique Garrel, md, cspq 
Professeur titulaire 
Directeur du Département de nutrition 
 
 
 
Personne ressource pour les  questions concernant l’éthique : 
Dr Vincent Castellucci 
Président du Comité d’éthique de la recherche 
Faculté de médecine 
Université de Montréal 
 
 
CONFIDENTIALITÉ 
Toutes les données recueillies dans cette étude seront codées par numéros 
d’identification qui vous seront assignés et qui seront seulement connus par les 
responsables du projet.  Votre nom ne sera pas divulgué avec aucun résultat.  Les 
résultats des analyses de sang ainsi que des mesures physiques (grandeur, poids, 
tension artérielle) obtenus dans cette étude seront partagés avec vous et transmis à 
votre médecin traitant suite à votre consentement écrit. 
 
 
COÛTS ET COMPENSATION 
Vous devrez défrayer les coûts reliés à votre transport au laboratoire et à l’institut.  Le 
stationnement à l’institut et au laboratoire est gratuit pour tous les participants tout 
comme le seront tous les tests effectués.  Aucune compensation financière ne sera 
versée au participant. 
 
ARRÊT DU PROJET 
SI DES INFORMATIONS NOUVELLES RELIÉES À CETTE ÉTUDES OU CES 
COMPOSANTES VENAIENT À COMPROMETTRE D’UNE FAÇON OU D’UNE 
AUTRE LA SÉCURITÉ ET LA SANTÉ DES PARTICIPANTS OU NE 
RESPECTERAIT PAS LES RÈGLES D’ÉTHIQUE, CETTE ÉTUDE SERAIT 
ARRÊTÉE IMMÉDIATEMENT. 
LIBERTÉ DE CONSENTEMENT 
JE RECONNAIS QUE MA PARTICIPATION À CE PROJET EST TOUT À FAIT 
VOLONTAIRE ET QUE JE SUIS LIBRE D’Y PARTICIPER.  JE CERTIFIE QU’ON 
ME L’A EXPLIQUÉ VERBALEMENT, QU’ON A RÉPONDU À TOUTES MES 
QUESTIONS, QU’ON M’A REMIS DES NOTES EXPLICATIVES 
COMPLÉMENTAIRES ET QU’ON M’A LAISSÉ LE TEMPS VOULU POUR 
PRENDRE UNE DÉCISION. 
ET 
JE RECONNAIS ÊTRE LIBRE DE ME RETIRER EN TOUT TEMPS SANS QUE 
CELA NUISE AUX RELATIONS AVEC MON MÉDECIN ET LES AUTRES 
INTERVENANTS ET SANS PRÉJUDICE D’AUCUNE SORTE.  DE PLUS, JE 
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COMPRENDS QUE LES DONNÉES ET LES ÉCHANTILLONS ACCUMULÉS 
ANTÉRIEUREMENT SERONT UTILISÉS MÊME EN CAS DE RETRAIT 
 
            
PARTICIPANT     TÉMOIN 
 
 
            
SIGNATURE      SIGNATURE 
 
 
JE CERTIFIE AVOIR EXPLIQUÉ AU SIGNATAIRE LES TERMES DU PRÉSENT 
FORMULAIRE DE CONSENTEMENT ET LUI AVOIR CLAIREMENT INDIQUÉ 
QU’IL RESTE À TOUT MOMENT LIBRE DE METTRE UN TERME À SA 
PARTICIPATION AU PRÉSENT PROJET. 
 
          
CHERCHEUR     DATE 
 
     
SIGNATURE 
 
TOUTES LES INFORMATIONS SERONT CONSERVÉES EN LIEU 
SÉCURITAIRE À L’UNITÉ MÉTABOLIQUE DU DÉPARTEMENT DE 
NUTRITION DE L’UNIVERSITÉ DE MONTRÉAL 
 
J’AUTORISE LA TRANSMISSION DES INFORMATIONS CONTENUES DANS 
MON DOSSIER À MON MÉDECIN DÉSIGNÉ 
 
            
PARTICIPANT     TÉMOIN 
 
            
SIGNATURE      SIGNATURE 
 
_______________________ 
DATE 
